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ABSTRACT
A reduction in tobacco use is one of the stated aims of the National Health Promotion
Strategy (2000-2005) (Department of Health and Children, 2000a) as well being the core
activity of membership for all health promoting hospitals (HPH).
AIMS OF THE STUDY
1. To develop a database of smoking cessation services in Ireland.
2. Do a census of the smoking cessation services in Ireland and evaluate the range and
availability of them.
3. Develop a database for use in smoking cessation treatment services which would schedule
consultations with patients and gather all relevant demographics, treatments and their
outcomes, (cessation treatment database) and pilot its use over a 3 month period.
4. Conduct a patient satisfaction survey of the service users.

RESEARCH METHODS:
1. The database of services was compiled from existing information supplemented by
further enquiry and validation. It was then used as the population base for a survey of
services using a specially developed, structured self-administered questionnaire which was
completed by the smoking cessation service providers identified from the database.
2. Having developed an “Excel” based smoking cessation treatment database, workshops
were held around the country and used to further develop and demonstrate it. At these
workshops smoking cessation service providers were encouraged to (SPs) into pilot its use
for a 3 month period. Data on patients was entered into the database by SPs during the 3
month pilot and was subsequently analysed.
3. A patient satisfaction survey was also carried out during this 3 month period using a
custom built survey instrument with the cooperation of the SPs.
2

FINDINGS:
1. A database of 93 smoking cessation service providers was established.
2. The subsequent census done found that all SPs had some specific training in smoking
cessation, more than 2 years’ experience and are employing evidence based interventions.
3. Of the 93 SPs identified 49 agreed to take part in the 3 month pilot of the cessation
treatment database. Completed treatment databases were received from 41 of the SPs into
which 1490 patients were entered. 400 patients reported smoking less than 20 per day,
while 1036 patients reported smoking more than 20 per day. Higher cigarette consumption
did not demonstrate any statistically significant difference in quit rates either at 4 weeks
(37%) or at 3 months (22.4%). Socio-economic (SE) groups 1-3 demonstrated quit rates of
41% at 4 weeks and 28% at 3 months while SE groups 4-6 demonstrated quit rates of 39%
at 4 weeks and 23% at 3 months making social class statistically associated with quit rates.
Patient status ( whether treated as an in-patient/out-patient or in the community) was
statistically significant at 4 weeks (P < 0.05) but not at 3 months in the case of inpatients
the quit rate fell from 40% at 4 weeks to 24% at 3 months.
4. A total of 342 patient satisfaction questionnaires were received and these demonstrated
that less than 7% of the patients had to wait for more than 4 weeks for an appointment and
almost all (94%) were satisfied and would be happy to return to the service.

CONCLUSIONS:
Database of cessation service providers
No up to date comprehensive database of service providers existed and there was no
circulation to health professionals of contacts to aid referrals.
3

Census of smoking cessation services
There is a need for services in psychiatric settings, for standardised follow up of patients
and training 61% identified need for further training. There was poor data collection, 32%
of SPs do not have access to a PC and poor use is being made of the data they do collect.
Treatment Database
Quit rates of 37% at 4 weeks and 22.4% at 3 months of all those entered into the database.
There were low quit rates in pregnant women at 16.5% and consistently poor outcomes in
vulnerable populations. There were low referrals from outside cessation services.
Patient Satisfaction Questionnaire
Patients preferred time of appointment was weekday mornings. Prescription cost did not
deter their participation in the treatment programme. 94% Patients were very happy with
service and would be happy to return.

4

Declaration:

I hereby certify that the material which is submitted in this thesis as a requirement for the
award of Masters in Philosophy. (MPhil) is entirely my own work and has not been taken
from the work of others, save and to the extent that such work has been cited and
acknowledged within the text of my work.
This thesis was prepared according to the regulations for postgraduate study by research of
the Dublin Institute of Technology and has not been submitted in whole or in part for
another award in any other third level institution.
The work reported on in this thesis conforms to the principles and requirements of the
DIT's guidelines for ethics in research.
DIT has permission to keep, lend or copy this thesis in whole or in part, on condition that
any such use of the material of the thesis be duly acknowledged.

Signature of candidate: ________________________________,

Date: _______________________

5

Acknowledgements:

I would like to acknowledge all the Smoking Cessation Service Providers who assisted
with the audit of services, the piloting of the treatment database and TFRI’s project
partners including: The Institute of Public Health in Ireland, The Irish Health
Promoting Hospitals Network, and the Health Service Executive. This project was
supported by a Partnership Award Grant between the Health Research Board and
the TobaccoFree Research Institute Ireland.
I would like to thank my supervisors Professor Pat Goodman, Dr Zubair Kabir and
Professor Luke Clancy for all their advice and support and in particular for reading
the manuscript and continued support and encouragement.

I would also like to offer a special note of thanks to my colleague Vanessa Clarke for
her support and friendship, and to Laura Currie who worked with me closely during
this project.
To my husband Dominic, sons Alan and Tom and my dear late Mother Anna
McGloughlin I wish to acknowledge a great debt for their patience, understanding
and support during my time writing this thesis.

6

Abbreviations
WHO

World Health Organisation

EU

European Union

CO

Carbon Monoxide

PPM

Parts Per Million

FCTC

Framework Convention on Tobacco Control

IHPH

Irish Health Promoting Hospitals

HPH

Health Promoting Hospitals

COPD

Chronic Obstructive Airways Disease

DOHC

Department of Health and Children

IARC

International Agency for Research on Cancer

SHS:

Second Hand Smoke
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Office of Tobacco Control

SE

Socio Economic

SPs

Service providers

CP

Cessation Programme

SCS

Smoking Cessation Service

NRT

Nicotine Replacement Therapy

ETS:

Environmental Tobacco Smoke

GP:

General Practitioner

PM:

Particulate Matter

SIDS:

Sudden Infant Death Syndrome

TFRI:

TobaccoFree Research Institute Ireland
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ENSP

European Network for Smoking and Tobacco Prevention

NICE

National Institute of Clinical Excellence

ECHP

European Community Household Panel

PESCE

General Practitioners and the Economics of Smoking Cessation in Europe

eSCCAN

European Smoking Cessation Clinic Assessment

EQUIPP

Europe Quitting and Progress Report

SJH/AMNCH St James’s Hospital, Adelaide Meath and National Children’s Hospital
Odds Ratio

The odds ratio is used to determine whether a particular exposure is a

risk factor for a particular outcome, and to compare the magnitude of various risk
factors for that outcome.
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CHAPTER 1

1.1

BACKGROUND ON TOBACCO AND SMOKING CESSATION

Background

Tobacco use is a major preventable cause of death and chronic disability in Ireland today
and a major cause of health inequality. Tobacco use is a major killer: in Ireland between
the years of 1950 – 2000 approximately 235,000 were attributed to it. Half of them died in
middle age (35-69yrs) and many of those killed in middle age would have lived on for 10,
20, 30 or more good years. About 22 years of life are lost, by those killed in middle age by
smoking (2006 www.deathsfromsmoking.net).
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The strategic aim of the National Health Promotion Strategy 2000/2005 was to increase the
percentage of the population who remain non-smokers with a particular emphasis on
narrowing the gap across social classes and to protect non-smokers from passive smoke. Its
objectives were to develop, implement and evaluate models of best practice in smoking
cessation for lower socio-economic groups (Department of Health and Children, 2000).
The review of the National Health Promotion Strategy 2004, noted that additional work was
needed to develop and disseminate national guidelines for smoking cessation training
(Department of Health Promotion et al., 2004).

Early development of smoking cessation services in Ireland occurred within the acute
hospital sector, as part of HPH membership with little funding. Momentum was gained
following the publication of the National Cardiovascular Strategy. This strategy called for
the provision and access to smoking cessation services countrywide and allocated funding
for this development (Department of Health and Children, 1999).

Unfortunately this

development was never fully realised. In 2003, further impetus was gained when the
availability of smoking cessation services countrywide was seen as a key national strategy
developed in conjunction with the introduction of the 2004 smoking ban in Ireland.

Smoking prevalence has been decreasing since the 1980’s. The most up to date national
rate is 24% (OTC et al., 2010), but the rate of decrease has been slowing since the mid1990s. However, rates of tobacco use are increasing in young women and in people from
lower socio-economic groups (Kelleher et al., 2003) (Layte and Whelan, 2004).
19

Environmental tobacco smoke has also been linked with lung cancer in non-smokers
(Hackshaw et al., 1997). The use of tobacco during pregnancy is one of the most important
risk factors for neonatal and late foetal deaths (Doll et al., 1994).

Smoking rates among women are increasing whereas among young men they are
decreasing (HBSC 2001/02). The 1998 European Community Household Panel (ECHP)
survey found that young Irish women (aged 16-24) had prevalence rates of 35% (2nd
highest of the 11 countries) for those with “low” educational attainment compared to 24%
for those with “high” educational attainment (Commission and Group, 1998). The 2000
ECHP found that there have actually been increases in smoking among lower income and
lower social class groups. Smoking among manual working class groups are twice those of
professional and managerial groups (Europen Commission and Group, 2000). The fact that
many studies show that smoking is more prevalent in the lower socio-economic groups
suggests that these are the groups that tobacco control policies should especially focus on.
Tobacco is a highly addictive substance and the difficulties associated with quitting are
well documented. In 1988 a report by the US Surgeon General identified cigarette smoking
as nicotine addiction (General, 1988). Cigarette smoking is a chronic relapsing disease and
has been classified as a mental and behavioural disorder according to the WHO
International Classification of Diseases, lCD-l0 (F17.228). The most important component
of daily smoking is nicotine dependence and most people need to attempt quitting several
times before they are successful (WHO, 1997). Smoking cessation services are an
invaluable resource for smokers who wish to quit, as it is very difficult to stop smoking
without help and about 90% who try will be smoking again 6 months later (Bandolier,
20

2008). Smoking cessation services can help smokers to quit their smoking habit which in
turn will help to reduce smoking prevalence. This will lead to the improvement of health
status; reduce morbidity, and premature mortality in the population. Disease risks are
reduced following smoking cessation and those smokers who stop before middle age can
avoid most of the excess risk they would have suffered (Doll et al., 1994). Cessation of
smoking at any age is associated with risk reduction.

Helping smokers stop can be

provided in different ways through brief interventions, behavioural therapy, self-help
materials, and pharmacotherapies. There is evidence that these are effective and improve
long term quit rates (Hughes et al., 2004). Most smokers want to stop but their chances of
success are low unless they are offered support and treatment. Brief advice,
pharmacotherapies and more intensive behavioural support have all been shown to increase
a smoker’s chance of stopping (Raw et al., 1999).

In 2001, the World Health Organisation highlighted that the provision of smoking cessation
services for adults could bring about quicker health gains than a complete focus on
preventing people from starting to smoke. Tobacco continues to kill nearly 6 million
people each year, including more than 600,000 non-smokers who die from exposure to
tobacco smoke. Up to half of the world’s 1 billion smokers will eventually die of a
tobacco-related disease (WHO, 2011).
Total tobacco-attributable deaths are projected to rise from 5.4 million in 2005 to 6.4
million in 2015 and 8.3 million in 2030 (Mathers and Loncar, 2006), unless more effective
measures are introduced to help smokers to stop smoking or at least reduce their tobacco
consumption.
21

The Warsaw Declaration for a Tobacco-Free Europe, 19 February 2002, acknowledged that
tobacco is a toxic and addictive substance and that the tobacco epidemic is one of the
greatest public health challenges facing the World Health Organisation’s (WHO) European
region. It was also emphasized that smoking cessation strongly contributes to a decrease in
smoking prevalence (WHO, 2002). It is clear from previous Cochrane reviews that both
simple advice and nicotine replacement therapy can improve the chances of quitting in
some patients (Silagy et al., 2004) (Lancaster and Stead, 2004) and should form part of a
primary care strategy for smoking cessation.
Behavioural strategies to aid smoking cessation range from very brief interventions, such as
advice from a physician, to intensive multi-component programmes. There is good
evidence for the effectiveness of brief, therapist-delivered interventions, such as physician
advice (Lancaster and Stead, 2004), and for the additional effect of more intensive
behavioural interventions, such as group therapy, (Stead and Lancaster, 2005) individual
counselling (Lancaster and Stead, 2005) and telephone counselling (Stead et al., 2003).
Most successful quitters give up on their own (Hatziandreu et al., 1990). Existing evidence
was summarised for both the older and newer forms of self-help interventions in promoting
smoking cessation and found that providing smokers with materials to support quit attempts
is of limited benefit unless the materials take into account each smoker's individual
characteristics (Lancaster and Stead 2005).

It was found that training health professionals to provide smoking cessation interventions
(to ask people if they smoke and offering them advice) had a measurable effect on
22

professional performance (trained persons were more likely to perform tasks of smoking
cessation than untrained controls) but did not find strong evidence that it changed smoking
behaviour (Lancaster et al., 2000). Having smoking cessation programmes in pregnancy
was found to reduce the proportion of women that continue to smoke, and reduce low birth
weight and preterm birth (Lumley et al., 2009). Advice and support from nurses may help
people to stop smoking, especially when they are in hospital (Rice and Stead, 2004). High
intensity behavioural interventions that include at least one month of follow-up contact are
effective in promoting smoking cessation in hospitalised patients (Rigotti et al., 2007).
Smoking related mortality is likely to rise substantially unless effective interventions are
put in place to reduce smoking prevalence (Ezzati and Lopez, 2003). Unfortunately,
training of health professionals in smoking cessation services is inadequate in Europe
(Kabir et al., 2011).
Smoking cessation interventions are effective both in terms of cost and outcome. Research
evidence shows that there are highly cost-effective ways to help people stop smoking
(Christenhusz et al., 2011). The potential savings to the drugs bill if more smokers stop is
considerable. Quitting smoking can eliminate the need for cholesterol-lowering medication
(statins) and result in significant cost savings (Nicklas et al., 1999). Smoking cessation
interventions are about 17 times more cost effective than statins (McNeill A, 2000).

1.2

Development of cessation services in Ireland

Through the ‘Europe against Cancer’ programme failed to achieve its target of reducing
cancer deaths by 15% by the year 2000 and as a result of this failure the European
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Community has set as one of its objectives reducing the number of cases of cancer and
other diseases related to smoking by stating that renewed tobacco control efforts are needed
along with increased screening.

The EU Council recommendations on prevention of smoking and on initiatives to improve
tobacco control, 2002, recommends that member states continue developing strategies and
measures to reduce the prevalence of smoking, such as general programmes to overcome
tobacco addiction. Article 14 of the Framework Convention on Tobacco Control (FCTC)
requires Parties to “include diagnosis and treatment of tobacco dependence and counselling
services on cessation of tobacco use, in national health and education programmes, plans
and strategies” and to “develop and disseminate appropriate, comprehensive and integrated
guidelines” in order to take “effective measures to promote cessation of tobacco use and
adequate treatment for tobacco dependence”.
By ratifying the WHO Framework Convention on Tobacco Control (FCTC), Ireland has
agreed to develop and disseminate appropriate, comprehensive and integrated guidelines
based on scientific evidence and best practices and to take effective measures to promote
cessation of tobacco use and adequate treatment for tobacco dependence. In addition
Ireland has agreed to design and implement effective programmes aimed at promoting the
cessation of tobacco use.

In June 2001 the WHO Tobacco Free initiative developed policy recommendations for
smoking cessation and treatment of tobacco dependence. These were published in June
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2003 and launched during the 12th World Conference on Tobacco or Health in Helsinki,
Finland. The recommended framework includes a mix of three main strategies:
(WHO, 2003a).
1. A public health approach that seeks to change the social climate and promote a
supportive environment;
2. A health systems approach that focuses on promoting and integrating clinical best
practices (behavioural and pharmacological) which help tobacco-dependent consumers
increase their chance of quitting successfully.
3. A surveillance, research and information approach that promotes the exchange of
information and knowledge so as to increase awareness of the need to change social norms.

In Ireland ‘Towards a Tobacco Free Society’, a report of the Tobacco Free Policy Review
Group has as one of its key targets to significantly increase the number of people who stop
smoking each year and to systematically evaluate services provided with a view to
promoting best practice (Department of Health and Children, 2000b).
A key method of achieving this target is the provision of cessation programmes to assist
smokers to quit. The Minister for Health and Children launched the National Smoking
Cessation campaign, ‘Every Cigarette is Doing You Damage’ in November 2003 and the
Health Service Executive (HSE) recently launched a campaign in June 2011’You can Quit’.
Smoking cessation services are available free of charge throughout Ireland and are provided
in both community and hospital settings. Different types of services exist and are provided
by health care professionals from different disciplines and community workers.
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Key objectives of Ireland’s National Health Strategy “Quality and Fairness: A Health
System for You” (Department of Health and Children, 2001) included intensifying the
promotion of health and well-being, reducing health inequalities and developing evidence
and strategic objectives to underpin all planning and decision-making. It also stated that a
reduction in smoking will continue to be targeted through Government fiscal policies.

The National Health Information Strategy advocates the establishment of processes that
ensure the fuller use of health information in policy making, service planning,
implementation processes, and health information standards that ensure the quality and
comparability of health information. It points out that information is needed on the
effectiveness of health promotion, protection and intervention initiatives (Department of
Health Promotion et al., 2004).

The National Cancer, Cardiovascular and Health Promotion Strategies and the report of the
Task Force on Sudden Cardiac Death (2006), emphasise the importance of reducing the
prevalence of smoking in order to improve health status and reduce premature mortality
(DOHC, 2006).

1.3

Smoking cessation

At any given time four out of five smokers would like to quit smoking. Two thirds of
smokers have tried quitting at some stage. For those who quit unaided there is less than a
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5% chance of being abstinent after one year (WHO, 1997). Smokers go through a quitting
process which may include some or all of the following:


thinking about quitting,



planning to quit,



attempting to quit,



remaining abstinent,



going back to smoking.

This cycle may be repeated many times. Smoking cessation intervention and treatment aids
have been shown to significantly increase the number of successful quit attempts. Cessation
programmes can provide either psychological and behavioural support and or provision of
pharmacological aids. Such programmes can be administered through a variety of primary,
secondary, and community care facilities.

Tobacco control legislation enables the government to implement and direct policies, set
tobacco prices and taxes, ban advertisement and sponsorship, and instigate mass public
education campaigns.

It was known that while services are available in all of the four Health Service Executive
(HSE) regions, it would appear that there is little uniformity or consistency countrywide in
the delivery of these services. In some regions, single services are expected to effectively
cover extremely large geographical areas while others are limited to very small community
based areas or to single hospital catchment areas. While full-time dedicated staff are
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available to provide services in some regions, in other regions the service is provided on a
part-time or voluntary basis only. In many cases, services appear to be very limited and
patchy and access is focused towards specific population groups, for example, cardiac or
respiratory patients.

The Irish Health Promoting Hospital Network (IHPH) managers of smoking cessation
services as well as the service providers themselves had previously suggested that there is
no systematic follow up, and current review and evaluation is dependent on local resources.
At present there is no national structure in place to assist in this process and consequently
no collation of local findings that could assist with an adequate review on the value and
effectiveness of current smoking cessation services. This information is crucial if Irish
health service planners are to have the necessary information that can ensure the integration
of cessation services into an improved quality healthcare, one that can adequately respond
to the challenge of reducing tobacco use which is already known as the single most
important public policy action that will bring about significant health gains.

Since the development of the Health Promoting Hospital (HPH)-Smoke Free Hospital
Initiative in 1999 dialogue and discussion has taken place around the issue and
developmental needs of smoking cessation services, primarily those within the hospital
setting.
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HPH Coordinators and Smoking Cessation Facilitators meet regularly to share and make
recommendations. Since 2002, the need for standardised guidelines for cessation services
was identified, as was the need for a national data collection system.
In 2005, HPH Smoking Cessation facilitators identified the fact that there was no central
data collection and storage system, which could help in evaluation of the service with a
view to further development and identification of needs of the service.
A number of discussions took place between the Director General of TFRI and the Director
of the HPH Network prior to development of a proposal where it was hoped to address
these issues. Subsequently meetings took place with the TFRI team and staff involved in
smoking cessation and health promotion.
To date in Ireland there has been no comprehensive national study of the availability,
appropriateness or effectiveness of smoking cessation services. Smoking cessation services
are available throughout Ireland. Different types of services exist, delivered by health care
professionals and community workers.

The research planned in this programme will make a significant contribution in improving
our understanding of the way smoking cessation services are delivered nationally.

The data generated by this research will enhance evidence based policy which will inform
the provision of smoking cessation services in Ireland. Improved planning and delivery of
these services will result through identification of standards based on international best
practice and the identification of inequalities in service provision. This is in keeping with
one of the objectives of our Health Strategy “Quality and Fairness” which advocates an
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evidence based approach - National Goal No 4 ‘High Performance’ ( Department of Health
and Children, 2001).
Chapter 2 outlines the health effects of smoking tobacco and the reasons behind the
government’s plan to significantly increase the numbers who stop smoking each year and to
systematically evaluate services provided.

Chapter 3 outlines treatment of nicotine addiction/dependence, different pharmacological
treatments available to aid sufferers quit their addiction as well as the different type of
treatment programmes provided. In this chapter I will also discuss typically expected
success rates from treatment programmes and how these rates are validated.

Chapter 4 outlines the study methodology of this project.

Chapter 5 presents results of the cessation service database, the census of cessation service
provider’s questionnaire, results of the 3 month pilot use of the treatment data collection
instrument and the patient satisfaction questionnaire.

Chapter 6 discusses the project results.

Chapter 7 discusses study limitations and conclusions of the project.

Chapter 8 shows future recommendations.
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CHAPTER 2

HEALTH EFFECTS OF SMOKING TOBACCO AND

GOVERNMENT STRATEGY TO INCREASE NUMBERS WHO QUIT ANNUALLY

2.1

Adverse health effects, diseases and deaths caused by tobacco smoke

In 1964 the first Surgeon General’s report on the adverse health effects from smoking was
published. Since then for over 50 years there have been thousands of studies supporting
these adverse effects. Tobacco use remains the single most preventable cause of death for
both men and women in America (Surgeon General, 2010).
The surgeon general’s report states that having looked at the evidence on the mechanisms
by which smoking causes disease that there is no risk free level of exposure to tobacco
smoke (Surgeon General, 2010).
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The WHO estimates that half of the world’s children (700 million) are exposed to SHS.
Children are especially vulnerable to the effects of SHS as they breathe more rapidly and
they inhale more pollutants per pound of body weight than adults. A child exposed to SHS
has an increased risk of asthma, lower respiratory infections, bronchitis, middle ear disease,
bacterial meningitis and SIDS as well as generally reduced respiratory function (cough,
wheezes). Children are more likely to smoke if their parents are smokers. In Ireland 29%
of adults still smoke totalling to almost 1 million smokers (Kabir et al., 2011).

If w our

smoking cessation rates were improved not only would this reduce the burden of disease on
the state it would also protect from exposure to secondhand smoke as well as preventing
some children from initiating smoking. Reducing the number of smokers in the county is
paramount to the health of the nation and in reducing the number of smokers would also
improve the health of our children. For example 14.8% (13.9% in young males, 15.4% in
young females) of Irish children aged 13-14yrs old were exposed to second hand smoke in
cars (Kabir et al., 2009). If there were fewer smokers this would lead to a reduction of
exposure to second-hand smoke to children in all areas including confined and enclosed
spaces such as cars.

Chronic diseases which result from active and passive smoking impose an enormous
burden on our health care system. Figure 2.1 shows the leading causes of death worldwide
as well as showing how many millions of them are related to tobacco use in 2005. A costeffective comprehensive tobacco dependence treatment program can accelerate further
declines in smoking rates (Currie et al., 2012).
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Tobacco use is a risk factor for six of the eight leading
causes of death in the world
Figure 2.1

Ischaemic
heart
disease

Cerebrovascular
disease

Lower
respiratory
infections

Chronic
obstructive
pulmonary
disease

HIV
AIDS

Diarrhoeal
diseases

Tuberculosis

Trachea
bronchs,
lung
cancers

Tobacco
use

Hatched areas in figure 2.1 indicate proportions of deaths which are as a result of tobacco
use, * includes mouth oropharyangeal cancer, oesophageal cancer, stomach cancer, liver
cancer, other cancers as well as cardiovascular diseases other than ischaemic heart disease
and cerebrovascular disease (WHO, 2008).
Tobacco use is the leading preventable cause of death in the world and was responsible for
over 5 million deaths worldwide in 2005, mostly in poor countries and among the poorer
populations. The number of deaths as a result of tobacco is likely to rise to 10 million by
2023 unless measures known and proven to reduce tobacco use are implemented (WHO,
2003b). 655,000 people die every year in the EU as a consequence of tobacco related
diseases (Peto et al., 1992).
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There is a 2-fold increase in death rate in middle-age of smokers (35-69) compared to nonsmokers (Doll et al., 2004).
Smoking is a strong risk factor for six of the eight leading causes of death around the world,
(see figure 2.1) which include:


Lower respiratory infections



Tuberculosis



Trachea, bronchus and lung cancers



Chronic obstructive pulmonary disease (COPD)



Ischaemic heart disease;



Cerebrovascular disease (WHO, 2008)

Figure 2.2

Diseases caused by smoking
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(WHO, 2011)

2.2

Tobacco and cancer

The global burden of cancer is escalating as a result of the dramatic increases in the use of
tobacco in the developing world. The use of tobacco is linked to many cancers mainly lung
cancer which is the single most common cancer in the world. The use of tobacco is
attributable to 87% of all lung cancer deaths. There is a dose response relationship between
cancer risk and tobacco use. A lifelong smoker is 20 – 30 times more likely to get cancer
than a non-smoker (Oppeltz and Jatoi, 2011).
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In 2004, the International Agency for Research on Cancer (IARC) judged that there was
sufficient evidence in humans that tobacco smoking causes cancers of the lung, larynx, oral
cavity and pharynx, paranasal sinuses, oesophagus, stomach, pancreas, liver, kidney, ureter,
bladder, uterine cervix and bone marrow and this list was recently updated to include
cancer of the colon and rectum (Parkin, 2011a). It is also responsible for other circulatory
diseases, stomach and duodenal ulcers, erectile dysfunction and infertility, osteoporosis,
cataracts, age-related macular degeneration and periodontitis.
Women who smoke during pregnancy have a substantially higher risk of spontaneous
abortion (miscarriage) than those who do not smoke. Smoking can also cause complications
in pregnancy and labour. Babies of smokers are 200 to 250gms lighter than their
counterparts and more than 25% of sudden infant deaths are attributable to smoking (NICE,
2008).
The risk of lung cancer relates to the cumulative exposure to tobacco smoke (duration and
dose), including the time since quitting in ex-smokers (Parkin, 2011b).

2.3

Tobacco and heart disease

Cigarette smoking is a well-known risk factor for cardiovascular disease both in terms of
morbidity and mortality (Doll et al., 2004, Freund et al., 1993). A study from 2012
concluded that those who smoke more intensely and have a history of a higher number of
pack years (pack years: the number of cigarettes a person has smoked over time. One pack
year is defined as 20 manufactured cigarettes (one pack) smoked per day for one year)
have a lower exercise tolerance and heart rate reserve with a blunted heart rate response to
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exercise. They also concluded that after 3 years, physiological treadmill stress testing
improvement, suggestive of improved Cardio Vascular disease prognosis were observed
among successful abstainers (Asthana et al., 2012). There is a nonlinear dose response
between exposure to tobacco smoke and cardiovascular risk, with a sharp increase at low
levels of exposure (including exposures from second hand smoke or infrequent cigarette
smoking) and a shallower dose-response relationship as the number of cigarettes smoked
per day increases (Surgeon General, 2010).

2.4

Tobacco and respiratory diseases

The two main lung diseases caused by smoking and exposure to Second Hand Smoke
(SHS) are Chronic Obstructive Pulmonary Disease (COPD) and lung cancer. 50% of
smokers will develop COPD, Smoking is responsible for 80% of COPD cases (2004). 72%
of male COPD deaths and 50% of female COPD deaths in Europe in 2000 were due to
smoking (Scanlon et al., 2000) and there is a two fold increase in the rate of lung function
decline in smokers compared to sustained (5 years) quitters (Peto et al., 1996).
Lung cancer is the biggest killer of all the cancer groups, accounting for about 20% of all
cancer deaths, and cigarette smoking is estimated to be responsible for approximately 90%
of lung cancer cases.

About 70% of the tar contained in the smoke ends up coating the

lungs. An average smoker’s lung collects about a mug full of tar each year. When it
condenses the tar forms a sticky brown substance. Tar contains many cancer causing
chemicals as well as irritants that causes smokers to cough.
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2.4.1 Smoking related respiratory diseases in Ireland

Respiratory disease is one of the biggest health burdens, it remains the most common
reason for a GP visit in Ireland and the third most common reason for hospital admission in
Ireland and deaths from respiratory disease now exceed those from coronary disease.
Ireland has the highest death rates from respiratory disease in Europe it being almost twice
the European average.
Mortality by type for Respiratory disease in Ireland:


Pneumonia

33%



Respiratory cancer*

28%



COPD

22%



Other lung diseases

17%

E.g. Asthma and pneumoconiosis

*Includes cancer of nasal cavities, pleura, larynx, trachea, bronchus and lung (Brennan et
al., 2008).
Respiratory symptoms are also one of the more commonly reported effects from exposure
to second hand smoke. In a study carried out in Ireland in 1995 they found that 46.3% of
non-smoking children were exposed to smoking in the home with parental smoking
accounting for most of the passive smoking. In this same study they looked at symptoms in
both smoking and non-smoking teenagers and found that bronchitis symptoms were more
commonly reported in active smokers compared to non-smokers with an odds ratio of 3.02
(95% CI 2.34-3.88) (p < 0.0001) or in passive smokers compared to those not exposed to
smoking with odds ratio of 1.82 (95% CI 1.32-2.52) (p < 0.0001). This was repeated in
1998 showing similar results thus documenting that increased bronchitis symptoms occur in
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teenagers exposed to active or passive smoking (Manning et al., 2002). Studies also show
that bar workers experience far fewer respiratory and irritant symptoms following the
introduction of the smoke-free laws (Goodman et al., 2009).

2.5

Smoking related deaths

More than 6 million people die every year from tobacco use and exposure to tobacco smoke
(one death every six seconds) and this is expected to rise over the next 20 years (Figure
2.3). There is a two fold increase in death rate in middle-age smokers (35-69) compared to
non-smokers (Doll et al., 2004).
Figure 2.3 Cumulative tobacco deaths between 2005 and 2030

(WHO, 2008)
39

It is known from Brennan et al that smoking related diseases are also the most common
causes of death in Ireland (fig 2.4).
Figure 2.4 Death by Cause in Ireland in 2004

(Brennan et al., 2008)

2.6

Principles of tobacco control

Several strategies have been shown to reduce tobacco use but 50 years after the adverse
health effects of tobacco smoke were proven few countries have established and
implemented effective strategies to control its use.
By ratifying the WHO FCTC, 176 countries including Ireland have committed to protecting
the health of their populations by joining the fight against the tobacco epidemic and the
WHO has produced the MPOWER strategy package to aid this important task.
M

Monitor tobacco use and prevention policies

P

Protect people from tobacco smoke
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O

Offer help to quit tobacco use

W

Warn about the dangers of tobacco

E

Enforce bans on advertising, promotion and sponsorship

R

Raise taxes on tobacco products

Monitoring- Monitoring is essential to provide baseline data which will enable targeting of
activities, tracking of progress and effectiveness of implementations of policies. Countries
best at monitoring prevalence of tobacco use can be seen in figure 2.5 and the monitoring
of tobacco use and tobacco control policies is critical to the success of the other 5
MPOWER measures.
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Figure 2.5 Prevalence of Tobacco use worldwide.

(WHO, 2011)
The countries coloured in orange represent those that best monitor the prevalence of
tobacco use.
Protection - Smokefree legislation should be in place and be fully enforced to enable totally
smokefree environments in health care and educational settings, and all indoor workplaces
including restaurants and bars. Exposure to second hand smoke is responsible for many
diseases including heart disease, lung cancer, and respiratory diseases. There is no known
safe level of exposure to second hand smoke.
Offer help to quit/cessation - Unless current smokers quit, tobacco deaths will rise
dramatically in the next 50 years. Health care systems should be strengthened to enable
easy availability of tobacco cessation advice and treatment to patients. Quit lines and other
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community initiatives should be supported along with low cost pharmacological therapy for
the treatment of tobacco dependence.

Warn - This involves implementation of health warnings on tobacco products and the
development of counter tobacco advertising. Plain packaging and graphic warnings on
tobacco products are needed to reduce the attractiveness of tobacco to children.

Enforce - Enforce legislation that comprehensively prevents any form of tobacco
advertising, promotion and sponsorship both direct and indirect such as product placement.

Raise - Price and Taxation - Increasing price and taxation will help smokers to quit
smoking, reduce the number of new smokers and thus reduce the number of people exposed
to secondhand smoke. Significant increases in tobacco taxes are a highly effective tobacco
control strategy and lead to significant improvements in public health. The positive health
impact is even greater when some of the revenues generated by tobacco tax increases are
used to support tobacco control, health promotion and/or other health-related activities and
programmes (Chaloupka et al., 2012).
Higher taxes increase government revenues. Contrary to tobacco industry propaganda,
tobacco tax increases do not decrease government revenues. Increasing tobacco taxes by
10% generally decreases tobacco consumption by 4% in high-income countries and by
about 8% in low- and middle-income countries (WHO, 2008). SimSmoke (SS) which is a
simulation model used to examine the effects of tobacco control policies on smoking
prevalence through, initiation, smoking cessation and associated future premature deaths.
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An adapted model IrelandSS was used recently in study of Irish data from 1998 and
projected to 2040. Using this, Ireland SS demonstrated that the result of the policies
implemented between 1998 through 2010, showed that 1716 fewer smoking attributable
deaths (SADs) are estimated by 2010 which is reasonably close to results from surveys
carried out. By 2040, the relative reduction in prevalence increases to 29%, with 50 215
fewer SADs. It also showed a 21.8% reduction in prevalence of male smokers from 1998
to 2010 of which only 9% were attributable to smoking cessation services. Whereas 45%
was attributable to price increase (Currie et al., 2012).
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CHAPTER 3

TREATMENT OF NICOTINE ADDICTION AND THEIR
EXPECTED OUTCOMES

3.1

Nicotine and Addiction

The chemistry and physiology of nicotine is well known and the addictive nature of the
drug has been well established. Absorption of cigarette smoke from the lung is very rapid,
after every inhalation a high concentration arterial bolus of nicotine is produced and this
reaches the brain within 10 – 16 seconds, which is faster than by intravenous injection.
Nicotine has a distributional half-life of 15 – 20 minutes and a terminal half-life in blood of
two hours. Therefore smokers experience a pattern of repetitive and transient high levels of
nicotine from each cigarette smoked which necessitates hourly smoking of cigarettes to
maintain raised concentrations. Overnight blood nicotine levels drop close to those of nonsmokers (Jarvis, 2004).

Since the 1980’s it has been accepted that tobacco products are among the most addictive
and deadly of all dependence producing substances (London, 2000). Nicotine is carried by
tar particles to the lung alveoli and then to the brain- a process that takes about 10 seconds
per inhalation (Russel et al., 1976). Nicotine binds to nicotine cholinergic receptors in the
brain which leads to the release of neurotransmitters (Benowitz, 2010,).
Nicotine has pervasive effects on brain neurochemistry. It binds to and activates the α4β2
nicotinic acetylcholine receptor stimulating release of dopamine in the nucleus accumbens,
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(Fig 3.1) this results in the satisfaction associated with smoking. A drop in nicotine levels
leads to craving and withdrawal (Jarvis, 2004).
Figure 3.1 Effect of nicotine on the brain

(Tomkins DM and Sellers EM, 2001)

Tobacco addiction is associated with an emotional as well as a physical dependence. It is a
complex process and to understand its complexity it is important to note the 3 important
factors that play a part in this addiction: The physical addiction to the drug nicotine, the
habit which includes handling, the ritual of opening the pack, lighting up, the sound of the
paper etc. and the psychological / emotional dependence often used as an aid to damp down
and or control negative feelings of anxiety, frustration or anger.
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Therefore, the ideal treatment for tobacco-cessation involves a comprehensive approach
that addresses all major issues of tobacco addiction both pharmacological and nonpharmacological.

Treatment populations for smoking cessation:

The target population for treatment should be everyone who smokes or uses any tobacco
product. Smoking cessations services should aim to treat 5% of population who smoke or
use other forms of tobacco. They should aim for a quit rate of 35% at 4 weeks and this quit
rate should be validated by carbon monoxide monitoring (NICE, 2008).

3.2

Brief intervention

Brief interventions involve opportunistic advice, discussion, negotiation or encouragement.
They are commonly used in many areas of health promotion and are delivered by a range of
primary and community care professionals. Brief intervention with regard to smoking
takes between 5 and 10 minutes and may include the following:


simple opportunistic advice to stop



an assessment of the patient’s commitment to quit



an offer of pharmacotherapy and/or behavioural support/referral
(National Institute for Health and Clinical Excellence, 2006)
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When you compare quit attempts which have been unassisted, to quit attempts following a
brief intervention, there is a difference in the cessation rate of about 2.5% between those
who received advice from a physician and those who did not (Lancaster and Stead, 2008).

3.3

Motivational interviewing

The definition of motivational interviewing has evolved over time. Initially it was described
by William R Miller in 1983 as an approach to behaviour change.

Motivational

Interviewing has been established as evidence based practice in the treatment of patients
with substance use disorders. It does not impose change but supports change which fits in
with the patient’s own beliefs, values and concerns.
A meta-analysis of 14 randomised trials showed that, as compared with brief advice or
usual care, motivational interviewing increased 6 month cessation rates by about 30%.
Cessation rates were higher if smokers received two or more sessions rather than one
session and if the sessions lasted more than 20 minutes (Hettima et al., 2005).

3.4

Intensive smoking cessation programmes

Group therapy offers individuals the opportunity to learn behavioural techniques for

smoking ‘group therapies’ have been described in the literature, most of which come from
four basic types of approaches:
Analytical: Its goal is to uncover and resolve hypothetical, unconscious conflicts
which are expected to lead to the patients’ recovery, i.e. attention to group members’

48

hidden motivation, interactions and attention to group members’ interactions with group
leaders.
Interpersonal: Social learning and feedback i.e. allowing group members learn
how their behaviour affects others.
Experimental: This is done mainly by working with the patients’ current awareness
of their experiences. The therapists using this approach are encouraged to use techniques
aimed at stimulating desirable group experiences.
Didactic: Usually connected primarily with behavioural and cognitive treatments.
Here the therapists usually have a set agenda for each group session, and the groups are
given tasks at each meeting.
More information on different approaches to group treatment, descriptions of group
processes and of practical skills involved in running groups can be found in Yalom and
Leszez (2005) and Aveline and Dryden (1988).

3.5

Pharmacological treatments

Nicotine Replacement Therapies (NRT)

Patches: Patches deliver a continuous even dose of nicotine over long periods of time and
there are many different doses and types of patches to choose from. You apply them to the
upper arm, hip, back or chest, the area chosen should be clean, dry and free of hair before
applying the patch, to ensure that it sticks. It is also recommended that the site of placement
of the patch be rotated to avoid any localised skin irritation. Patches should not be placed
on broken skin and patients are advised not to smoke while wearing a patch.
49

NiQuitin Patches are either opaque in colour or completely clear which allows for more
discrete use. They come in 3 different strengths 21mg, 14mg and 7mg and are delivered
over a 24hr period regardless of strength. NiQuitin suggest the following treatment plan
when using their product:
•

For 6 weeks, start with the Step 1 (21mg) NiQuitin Patch if you smoke 10 or more

cigarettes a day. (Go straight to Step 2 (14mg) if you smoke less).
•

For a further 2 weeks, change to the Step 2 (14mg) NiQuitin Patch. (Alternatively

start with Step 2 (14mg) for 6 weeks if you are a light smoker).
•

Finally, move onto the Step 3 (7mg) NiQuitin Patch for 2 weeks.

Nicorette Patches; Invisipatch is a semi-transparent 25mgs patch and delivers the dose
over a 16hr period which is advised to be applied first thing in the morning and removed
prior to going to bed.

Inhalers: These resemble a cigarette and into the inhaler are placed cartridges containing
nicotine which are then inhaled using a similar action to smoking. The inhaler is made up
of a mouth piece and a replaceable nicotine cartridge. When the patient draws on the
mouth piece of the nicotine inhaler the cartridge releases nicotine which helps relieve
cravings while at the same time the patients hands are kept busy. The inhaler available in
Ireland is the Nicorette inhaler. It is recommended that 6 to 12 cartridges be used per day
and it is particularly useful for those smokers that miss the hand to mouth movements of
smoking.
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Gum: This comes in two strengths 2mgs and 4mgs and this can be taken up to 15 times per
day. To release the Nicotine from the gum it should be chewed slowly until the taste
becomes strong then the gum needs to be parked between the cheek and gums to allow for
absorption of Nicotine. Once the taste fades the gum needs to be chewed again to release
more Nicotine and then parked again to allow for its absorption this can be repeated using
the same piece of gum for about an hour after which it is recommended that you use a new
piece of gum. Gum products available are NiQuitin Gum and Nicorette Gum both come
in both strengths of 2 and 4mgs, Nicorette also produce an Icy White Gum which in
addition to releasing nicotine helps to improve teeth whiteness.

Micro Tabs/ Lozenges:
Nicorette Micro Tab is a sublingual nicotine replacement tablet. It is particularly useful
for those who want a discrete delivery of nicotine. A tablet is placed under the patients
tongue and allowed to slowly dissolve. Patients are instructed not to swallow chew or suck
the tablet, nicotine will be released and absorbed through the lining of the mouth. It only
comes in one strength and it is recommended that smokers who smoke less that 20 per day
use one Micro Tab per hour while those who smoke more than 20 per day may take 2
Micro Tabs per hour the amount not to be exceeded per 24hrs, being 40.

NiQuitin Lozenges: These come in 2mg and 4mg strength and it is recommended that the
more heavily addicted smoker use the higher dose. The recommended dose is 1 lozenge
every one to two hours about 9 per day but can be used up to a maximum of 15 lozenges
per day.
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NiQuitin Mini: These are small mint flavoured Nicotine Lozenges that relieve Nicotine
cravings within minutes and deliver their full dose 3 times faster than gum. There are 2
doses of NiQuitin Minis available 1.5mg and 4mg. It is recommended that if you smoke
less than 20 cigarettes per day that you use 1.5mg and that if you smoke over 20 cigarettes
per day that you use the 4mg.

Varenicline (trade name Champix) Tablets contain the active ingredient Varenicline.
Varenicline is a type of medicine called a nicotinic acetylcholine receptor partial agonist.
This means that it acts on the same receptors in the brain as nicotine. Varenicline works by
stimulating the nicotinic receptors in the brain.
When you smoke a cigarette, the nicotine quickly reaches your brain and tells certain
receptors there to start releasing dopamine, a chemical that makes you feel good. What
Varenicline does is stop those receptors from responding to the nicotine. That means you're
not going to get that "rush" or "buzz" normally associated with smoking. Once the ‘buzz’ is
gone, the temptation to sneak a cigarette is going to be less and less. Varenicline has high
and selective activity at alpha4–beta2 receptor. It is a partial agonist at this receptor in vivo
producing a lesser response than that of nicotine (30–60%) but also blocks the effect of any
nicotine added to the system (Jiloha, 2010). Thus, Varenicline maintains a moderate level
of dopamine release, which reduces craving and withdrawal symptoms during abstinence.
It also blocks the reinforcing effects of nicotine obtained from cigarette smoke in the case
of relapse.
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Champix is only available on prescription. A complete course of treatment is for 12 weeks.
It is prescribed as a 2 week starter pack during which time the smoker may continue to
smoke but the smoker needs to set a quit date between day 8 and day 14 of the treatment.
Day 1 – 3

One 0.5mg tablet to be taken in the morning.

Day 4 – 7

One 0.5mg tablet to be taken twice daily, in the morning and once in the

evening at about the same time each day.
Day 8 - 14

One blue 1mg tablet to be taken twice daily, one in the morning and one in

the evening at about the same time each day. This dose is continued from week 3 to week
12. The prescription for the 2nd and 3rd months comes in a continuation pack.
It is recommended that patients complete a 3 month course of Champix. There is also
evidence that if successful for 12 weeks a further 12 weeks of treatment has added
advantage in preventing relapse.

Bupropion (trade name Zyban). The recommended treatment period is 7 to 9 weeks.

Dosage: Initially 150mg once daily for 6 days then 150mg twice daily (8hrs apart) for the
remainder of the 7 – 9 weeks. During the first 2 weeks of treatment the smoker continues to
smoke but should be aware when commencing the treatment that their quit date will be 2
weeks into the treatment period. The maximum single dose is 150mgs and the maximum
daily dose is 300mgs.
Neither Varenicline nor Bupropion should be offered to young people under 18 nor to
pregnant or breastfeeding women.
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Other methods of treatment available for smoking cessation are; Acupuncture,
Hypnotherapy and Rapid smoking, a form of aversion therapy. For both hypnotherapy and
acupuncture there is evidence that they do not improve long term quit status more than a
placebo. As far as rapid smoking goes there is good evidence that this can improve
abstinence rates but it is not recommended as it conflicts with smokefree regulations
(NICE, 2008).

Quitlines

Quitlines have been shown to be effective and there is a national Quitline in Ireland which
is run by the Health Service Executive in conjunction with the Irish Cancer Society.
Several meta-analysis have established that proactive telephone counselling is an effective
intervention for smoking cessation (Keller et al., 2010). Quitlines have the advantage of
being able to reach a large number of the population. Overall quit rates achieved by
patients using different interventions are shown in figure 3.2
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Figure 3.2 Different interventions used by smokers reporting continued cessation for 6
months.

Reproduced from (WHO, 2011)

3.6

Cessation rates

In the Lung Health Study of patients with chronic obstructive pulmonary disease (COPD)
the effect of smoking cessation was striking; and it showed that the development of
clinically significant airways obstruction was largely prevented in those who quit as
compared with those who did not. It also showed beneficial lung function improvements in
both sexes and concluded as a result that it is probably ‘never too late’ to use cessation as
an intervention for COPD (Anthonsien, 2004).
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In a study carried out in the UK which was published in 2000, it was shown that by 1990
smoking cessation had almost halved the number of lung cancers that would have been
expected if the former smokers had continued. It also showed that people who
stopped smoking, even well into middle age, avoid most of their subsequent risk
of lung cancer, and stopping before middle age avoids more than 90% of the risk of lung
cancer attributable to tobacco (Peto et al., 2000).
In the UK between 2003 and 2006 over 800,000 smokers availed of the NHS smoking
cessation services. Between 2005 and 2006 of those who set a quit date 55 % had quit at 4
weeks. The cost to the NHS per quitter for delivery of this service was £158.00 (The
information Centre, 2006).
Intervention from health professionals has been shown repeatedly, in randomised controlled
trials, to increase the percentage of smokers who stop and remain abstinent for 6 months or
more (West et al., 2000).
Approximately one in three European smokers have tried to quit in 2008 and of those that
have tried 51% remained abstinent for less than or equal to 56 days, 28% remained
abstinent for 1 to 8 weeks, only 19% remained abstinent for more than 8 weeks and <5% of
these can be expected to be successful at 12 months (Andreas et al., 2009).

3.7

Predictors of successful quit rates

Possible predictors of successful quit rates are many and varied such as:

Gender, age,

socio-economic group, smoking status (level of addiction), family environment, treatment
offered, medical advice, primary reason for quitting, number of previous quit attempts,
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support and or pharmacological interventions. The ability of the individual to pay for
treatment or whether the treatment is available free to some individuals may also impact on
successful quit rates.
Quitting produces immediate and significant health benefits and reduces most of the
associated risks within a few years of quitting (General, 1988).
In the USA studies show that successful quitters were more likely to be well educated at
least to college level, have rules against smoking in their homes, be less likely to have
switched to light cigarettes for health concerns, and more likely to be aged 35 years or
older, and be married or living with a partner (Lee and Kahende, 2007).

3.8

Validation of quit status

3.8.1 Cotinine:
Cotinine is a breakdown product of nicotine and therefore is a reliable biomarker for
nicotine and this makes it an accurate way of measuring exposure to tobacco smoke.
Cotinine levels can be measured in blood, urine, hair and saliva and levels can be measured
to validate smoking status. The most common sample for cotinine measurement is saliva
due to ease of sampling. More often cotinine levels are not used as a means of validating
quit status as it is time consuming and expensive but is used extensively in population
studies e.g. detection of exposure to secondhand smoke in children.
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3.8.2 Breath carbon monoxide measurement and smoking:

Carbon monoxide is a gas that is released from burning tobacco. When it is inhaled it enters
the blood stream and interferes with the working of the heart and the blood vessels. Carbon
monoxide (CO) is a colourless, odourless gas that is produced as a result of incomplete
combustion of carbon-containing materials, such as tobacco and is thus a very important
metric to quantify (McCaffrey et al., 2012).

Up to 15% of a smoker’s blood can be

carrying carbon monoxide instead of oxygen. The level of carboxyhaemoglobin (COHb) in
the blood has also been shown to be a useful marker of tobacco smoke absorption (Wald et
al., 1981).
The breath CO monitor is a good tool for use in smoking control assessments and a reading
greater than 5 ppm strongly suggests that the patient is a smoker and on questioning those
whose readings were between 5.5 and 18ppm admitted having smoked a cigarette on the
day of the test (Low et al., 2004). This is the validation method of choice for smoking
cessation services due to its low cost, ease of use and instant results. Most cessation
services use CO monitors for validation purposes and this is strongly recommended.

3.8.2.1

Equipment – CO monitor

Most cessation treatment providers use co monitors to validate a patient’s quit status.
The one I use when treating is the Care fusion CO monitor.
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3.8.2.2

Method

A patient is instructed to take in a deep breath, hold it for at approximately 20 seconds and
then exhale slowly and completely into the CO monitor. The monitor displays parts per
million (PPM) of Carbon Monoxide on its clear LCD display, and when used in
conjunction with the smoking cessation guide chart, %COHB are readily available.
The CO Monitor features single-button operation and coloured light indicators to simplify
patient understanding of the process:


Green: 0 to 6ppm



Amber: 7 to 10ppm



Red: 11 to 20ppm



Flashing red and alarm: >20ppm

3.8.2.3

Calibration of CO monitors

CO Monitors do not need frequent calibration and usually they come with a guarantee from
the manufacturers saying that the factory calibration is valid for 6 months. Once this time
has passed they need to be sent back to the manufacturers for re-calibration or if the
calibration gas is on site they can be calibrated in a medical physics department. It is
recommended that they are calibrated every 6 months to ensure accuracy.
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3.8.3 Self-Reported

Quit Status

Many cessation treatment providers gather their quit rate statistics by telephone
consultations. This means that a lot of the quit rates recorded are self-reported by the
patients and this has its limitations. An example of this self-reporting limitation was
demonstrated in a study of primary care patients with COPD where it was shown that they
do not provide valid information on their smoking status, which hinders the service
providers ability to provide adequate therapeutic interventions (Hilberink et al., 2011). Use
of biochemical validation either by monitoring of breath CO or measurement of cotinine
levels in daily care could overcome this problem.
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CHAPTER 4

STUDY METHODOLOGY

In this chapter I will discuss the development of a smoking cessation providers database, a
national census of the cessation services which will assess their range and availability, the
development of a cessation treatment database, pilot of its use and a patient satisfaction
questionnaire for the service they attended. In each of the above I will outline the methods
used, the populations surveyed and or treated and the instruments used to do so. All data
collected stored and analysed in this study were treated with care and consideration for the
patients and service providers from whom they were collected. All computers used had
secure usernames and passwords and were protected by Symantec endpoint. Data were
stored on a secure password protected server which is stored in a network operations centre
(NOC). The NOC is a secured locked room with restricted access.

4.1

Study plan



To establish a comprehensive database of cessation service providers.



Census of services including patient numbers, referral paths and training of service
providers.



A data collection tool/treatment database for use by service providers.



Piloting of data collection instrument/treatment database and analysis of data gathered
using it.



A patient satisfaction survey of the service they received for smoking cessation.
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Gant Chart: This project was designed to run over a 30 month period to include several elements
Months
Refine and futher develop
Database of Cessation service
providers
Development of Census
questionnaire to access range
and availability of services and
guidelines

1

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

Pilot Census Questionnaire
Analyse and revise Census
questionnaire
Circulate Census Questionnaire
& collect data
Data Entry of Census
Questionaire data
Develop a smoking cessation
treatment data collection
Instrument( Treatment database)
Develop Guidelines for
completing Treatment database
Organise and conduct
Workshops nationally for
cessation service providers
Circulation of Treatment
databases along with guidelines
and Patient satisfaction
questionnaires
Treatment data collection
cleaning and entry
Annalysis of treatment data
base and patient satisfaction
survey.
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4.3

A database of smoking cessation service providers:

Targeting, validating and expanding on the number of service providers identified in a
previously developed database.

4.3.1 Instrument: Excel Based Database.
The database of Ireland’s smoking cessation service providers was to be a full and
comprehensive one of existing services including the location of service, name of service
providers, their contact details, phone, email addresses and details of the line managers.
For the purposes of the development of a smoking cessation services database, a smoking
cessation service was defined as a service that could be based in a healthcare or community
setting, providing a service either on an individual one to one basis, over the telephone or
in a group, that the service be delivered by a specially trained person who will give smokers
the knowledge and support required to change their smoking behaviour in such a way as to
increase their chances of a successful quit attempt (Currie et al., 2010).

4.3.2 Methods
An existing incomplete Irish Health Promoting Hospitals Network database of hospital
based service was provided to TFRI and this database was then expanded and updated. An
advertisement was placed in Health Matters which is a Health Service Executive science
newsletter which provided a description of the project and a request for contact details with
regard to known smoking cessation services be sent on to TFRI. In an effort to identify
services in General Practice contact was made with the Irish practice nurses and the Irish
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College of General Practitioners. All known private health care clinics and hospitals were
also contacted to establish the existence of any private services.
Every effort was made to ensure that the database was as comprehensive as possible so that
the reliability of the planned census of cessation services would be valid.

4.4

National census questionnaire

A census of all known smoking cessation programmes was undertaken to assess the range
and availability of smoking cessation services nationally.
Population: 93 smoking cessation programmes were identified through HSE and HPH
Network and from further research by TFRI which completed the database of all known
smoking cessation programmes for this project.

4.4.1 Survey Instrument: Questionnaire
A previously validated questionnaire was sought in UK, Canada and elsewhere via
Globalink - an online international Tobacco Control network.

As there was not an

appropriate validated survey tool available to us a questionnaire of our own was developed
(Appendix 1). This questionnaire was developed in partnership with TFRI and members of
the Irish Health Promoting Hospitals Network (IHPHN), Institute of Public Health (IPHI)
and the Health Service Executive (HSE). Questions covered the following areas:


Background and training of staff providing the service



Range, intensity and frequency of services offered



Service setting, location and resources
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Once the questionnaire was designed it was piloted among 6 cessation service providers to
test its validity and they were asked to return completed questionnaires within 2 weeks
commenting on the appropriateness of questions, its ease of completing and any content
that they felt was not covered. Following the piloting of the questionnaire comments from
the service providers were discussed with staff from TFRI, and IHPH and the questionnaire
was subsequently revised and modified as appropriate. The questionnaire and explanatory
letter on how to complete it were mailed to all known smoking cessation facilitators in
electronic format to 77 cessation service providers and by hard copy in the post to 16
cessation service providers where it was established that they did not have access to a work
computer or email address. Respondents were asked to return the completed questionnaire
by email or by post to the TFRI office when email was not available to them.

4.4.2 Delivery/Reminders:
Up to two reminders were sent to programme facilitators one week post deadline and a
second 2 weeks post deadline, to return the questionnaire. These were then followed up by
at least 2 phone calls in a bid to get as large a response as possible.

4.4.3 Data Quality:
Quality control procedures for data entry were put in place including checking data fields
for invalid entries, crosschecking dates to ensure that they were within the time frames
required as well as double entry for all responses.
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4.4.4 Data Analysis:
Data were inputted by hand directly from the electronic and hard copy version of the
questionnaires into excel. Data were entered with double entry for accuracy and analysed
using Statistical Packages for the Social Sciences (SPSS Version 19.0) which provided the
descriptive data presented.

4.5

Smoking cessation treatment data collection instrument (treatment

database)
A data collection instrument was developed to allow for the assessment of smoking
cessation programmes.

A convenience sample of 1,490 patients was recruited cross-

sectionally while attending smoking cessation (SC) services throughout Ireland for a 3
month period in 2008. All but two of the service providers who participated in the pilot of
the treatment database did so between January and April while two others who had delays
in starting its use piloted the treatment database between and May and August.

4.5.1 Getting ‘buy in’ of smoking cessation service providers:
Convening and conducting workshops for smoking cessation facilitators/co-coordinators:
Three workshops were held nationwide, in Limerick, Dublin and Sligo. These workshops
were hosted by the HPH Network and TFRI staff. Using the newly completed and a now
comprehensive database of the 93 smoking cessation SPs, they were all contacted and
invited to the workshop location which would be most convenient for them to attend. The
purpose of the workshops was to get agreement and “buy in” from smoking cessation SPs
to participate in the study and to complete the treatment data collection instrument
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(treatment database) (Appendix 2) for all patients attending their service over a 3 month
period. At these workshops TFRI and staff from HSE and HPH demonstrated the use of
the data collection instrument.

Guidelines/instructions were written (Appendix 3) for

completing/entering data into the database and these were circulated among the 93 service
providers prior to the workshops. At each workshop time was taken to go through the
guidelines/instructions in detail with the SPs. They were also given time to handle and
enter data into the treatment database and any concerns or queries they raised were dealt
with. The coding systems of the data collection instrument as well as the patient satisfaction
questionnaire were explained.

4.5.2 Instrument: Excel database.
Using best practice criteria from the literature, the NICE guidelines, looking at existing
datasets from Northern Ireland and Denmark as well as those used by some of the Smoking
cessation service providers in Ireland, TFRI in consultation with HSE, IPH, and HPH
developed a data collection instrument.

In particular it was found that the most

comprehensive dataset which was being used in Ireland at the time was by the smoking
cessation services in the North West. The data collection instrument was designed to
collect all relevant information in a format that was quick and easy to complete. In its
design, cognisance was taken of the need for a simple and timely completion method in
order to aid compliance. The instrument was designed to gather information such as
whether the patient had previous quit attempts and if so whether they used Nicotine
Replacement Therapy and whether the patient availed of one to one or group counselling,
the number of visits to the cessation service, smoking profile, level of addiction and referral
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source. It also was designed to gather patient demographic details such as sex, age and
social class and follow up information on patient smoking status at 4 weeks and 3 months.
With regard to monitoring patients, the Russell Standard from the UK was detailed, which
has been adopted as guidance. It specifies times during which follow-up reviews should
take place. To save time, the data tool was programmed to automatically generate dates
indicating the start and end of the 4 week and 3 month follow up periods according to the
Russell Standard once a quit date has been entered.

Each service provider was given their own unique identifying code which was developed
using a minimum of 2 letters per centre. The first patient entered was given the added
numerical identity of 001, e.g. a code would read AA001, and the last code allocated was
ZZA001. These codes were for use when entering patients into their system to protect the
identity of the patient/patients being entered.

4.5.3 Recruitment of subjects
A study of all patients attending participating smoking cessation programmes was
conducted.

4.5.4 Population:
The population consisted of all consenting patients attending the 49 participating smoking
cessation programmes during the 3 month pilot use of the treatment database. Data on 1490
patients were collected.
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The data collection instrument/treatment database with guidelines was circulated to the
participating 49 smoking cessation service providers. The co-ordinator/service providers
were asked to collect data for each patient attending their smoking cessation service during
the 3 month pilot period. Data were collected at the point of entry to the service. To
ascertain whether a patient has remained abstinent, the co-ordinator needed to contact each
patient at 4 weeks and 3 months after the patient has completed the smoking cessation
programme. It was requested that this contact be done in person where possible to enable
CO validation of their smoking status so as to enable recording of patient quit status into
the treatment database. The data were collected electronically on an Excel based spread
sheet.

Each of the 49 participating service providers was emailed their personalised

treatment database. The cessation providers returned the uniquely coded anonymised
patient data sets to the study centre at TFRI. Data received from 39 providers were suitable
for analysis, the 2 databases received which were unsuitable for analysis used an Access
database and it was not possible to match the variables from the 2 different data sets and so
they had to be excluded from the analysis. The remaining 8 providers who had initially
agreed to participate failed to do so.
Timeframe for data collection: A three month entry period whereby data on all patients
who consented to be a part of the project and were using the smoking cessation service was
collected. Each patient was “followed up” at 4 weeks and 3 months post their quit date
during the smoking cessation treatment programme and cessation service providers were
asked to validate the patients smoking status at these designated times by using a CO
monitor. These readings were to be taken by each service provider. A successfully
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validated reading was deemed to be <6ppm and a failed quit attempt was deemed to have a
reading of >7ppm (Middleton and Morice, 2000).

4.5.5 Main outcome measures:
The main outcome measures of the treatment database were the 4 week and 3 months quit
rates. Definition of quit used at 4 weeks: According to the Russell Standard, a patient is
counted as a ‘4 week quitter’ if they have been assessed 4 weeks after their quit date (minus
3 days or plus 7 days) and declares that he/she has not smoked a single puff on a cigarette
in the past 2 weeks.
Definition of quit used at 3 months: A patient is counted as a ‘3 month quitter’ if they
have been assessed 3 months after their quit date (minus 14 days or plus 14 days) and
declares that he/she has not smoked more than 5 cigarettes in the past 10 weeks.
Other covariates studied were:


Demographics: Gender /Age/Ethnicity.



Pregnancy status



Referral source of patients



Patient status i.e. in patient/community/outpatient



Smoking History



Fagerstrom Score is a method of measuring the degree of tobacco addiction/dependency
0-3 mild level of addiction; 4-5 moderate level of addiction; 6-10 high level of addiction.



Treatments used on this attempt and on previous quit attempts



Number of previous quit attempts
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CO Validation; Service providers were asked that CO validation should be attempted on all
patients who have said they are quit at their 4 week follow-up/review CO monitoring of
patients at the 4 week and 3 months follow-up stage is considered to be good practice, as it
is motivational for patients as well as a validation of their smoking status



Occupation/Social Class. The entire population was classified into one of the following
social class groups (introduced in 1996) which are defined on the basis of occupation:
1. Professional worker
2. Managerial and technical
3. Non-manual
4. Skilled manual
5. Semi-skilled
6. Unskilled
7. All others gainfully occupied and unknown
The occupations included in each of these groups have been selected in such a way as to
bring together, as far as possible, people with similar levels of occupational skill. In
determining social class no account is taken of the differences between individuals on the
basis of other characteristics such as education. Accordingly social class ranks occupations
by the level of skill required on a social class scale ranging from 1 (highest) to 7 (lowest).
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4.6

Patient satisfaction questionnaire

4.6.1 Population:
All patients who were treated during the pilot of the treatment database were asked to
complete a satisfaction questionnaire. A sample of patients from each smoking cessation
programme who indicated their willingness to participate in a satisfaction survey as well as
signing the relevant consent form.

4.6.2 Survey Instrument: A specially developed, self-administered questionnaire
(Appendix 4).
Timeframe for data collection: Patients were asked to complete a previously piloted
questionnaire once they had completed the smoking cessation programme. These were all
patients entered into the treatment programme during the 3 month pilot of the treatment
data collection instrument who agreed to complete the satisfaction questionnaire.
All patients who agreed to complete the satisfaction questionnaire were issued with them
by their smoking cessation provider either by hand on entry into the treatment programme
or by post on completion of their treatment. They were requested to return the completed
questionnaires anonymously to the research institute TFRI and not to their providers of
care. The questionnaires were issued with the same corresponding unique code as the code
used entering their data for the 3 month trial of the treatment database. The anonymity of
the patient was maintained at all times using these unique identifying codes which were
issued in batches to the providers who then allocated them to the patients. No data was
received from providers with either names initials or addresses of patients. This was done
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with a view to comparing the satisfaction questionnaires with the outcome of their
treatment while at all times protecting their personal individual identity. At the time of
issue of the patient satisfaction questionnaire by the provider to the patient they were also
given a stamped addressed envelope to TFRI which they posted themselves and did not
have to hand back to their service provider.
4.6.3 Delivery/Reminders:
It was requested that at least 1 telephone reminder (at 1 week post treatment completion or
failure to return for follow up) be made requesting patients to return questionnaires.
4.6.4 Data Quality:
Quality control procedures for data entry were put in place including double entry for all
responses allocation of unique identifier, reconciliation of survey response with treatment
data already collected and identifying code verification.
4.6.5 Data Analysis:
Data were entered directly into SPSS by hand from the 342 hard copies received by post of
the patient satisfaction questionnaires and this statistical package was used to analyse data
findings.
4.6

Ethics submission and approval.

Various ethical approval committees were considered and an ethics submission was made
to the SJH / AMNCH RESEARCH ETHICS COMMITTEE for approval of the project on a
national basis. A study protocol was put together and submitted along with the completed
ethics application form. During completion of the ethics approval application form a
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patient information sheet was developed along with a patient consent form. The completed
application form, information sheet and consent form were submitted and approval was
received (Appendix 5).
4.7.1 Subject consent/subject information sheet
All patients attending smoking cessation services were asked permission to have their data
entered into the electronic database which was being piloted over a 3 month period and to
complete a patient satisfaction questionnaire in relation to the smoking cessation service
they had received. If they were agreeable then they were given an information sheet and
consent form to sign giving permission for their data to be entered into the local database
and then to be sent to and be analysed by TFRI.
After consultation with cessation service providers around the country some individuals
raised concerns with regard to approval of the project on a national basis and requested that
Ethical approval be sought in their individual institutions. This applied to St. Vincent’s
Hospital, Beaumont Hospital and the Mater Hospital. Further ethical approval was sought
and received by each of the above although St. Vincent’s Hospital decided not to
participate in the pilot use of the treatment database as they felt that their patients would not
be able to understand the information provided and thus would be unable to give their
consent.
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CHAPTER 5

RESULTS

In this chapter results will be presented on all 4 limbs of the project.
1.

Smoking cessation service database

2.

Census of smoking cessation services in Ireland

3.

Pilot of treatment database

4.

Patient satisfaction questionnaire

5.1

Smoking cessation service database

Once all avenues of enquiry were exhausted a finally completed database on which data
was gathered on 93 smoking cessation service providers (SPs). No service providers were
identified in private health clinics. The database contains the name of the service provider,
location of the service and contact details including address, phone number and email when
available.
5.2

Census questionnaire analyses

5.2.1

Sample:

Of the possible 93 cessation SPs canvassed, it was established that questionnaires could be
sent for completion electronically by email to 77 cessation SPs and 16 were sent out for
completion by hard copy in the ordinary post because email addresses were not available.
Following the sending out of the questionnaires two follow up phone calls were made
where it was established that 13(14%) of cessation SPs needed to be removed from the list
of possible responders due to extended leave, shared service coverage or discontinuation of
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service. Therefore a population of 80 eligible cessation SPs were thought to constitute the
population for this survey. Of these 68 responded to the questionnaire, giving a response
rate of 85%.

5.2.2

Training of service providers

All 68 SPs had some specific training in smoking cessation with more than 2 years’
experience and are employing evidence based interventions. 62.1% (n=41) expressed a
need for further training while 37.9% (n=25) were happy with their current level of
training.
Graph 5.1

Most recent training received by service providers.
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Table 5.1

Most recent training received by SPs.

Date of last Training

Frequency

%

Pre 2000

2

3

2001

0

0

2002

2

3

2003

6

9.1

2004

9

13.6

2005

9

13.6

2006

23

34.8

2007

15

22.7

Total

66

100

27.3% (n=18) within last 3 to 4 yrs.
15.2% (n=10) 4 or more years ago.
Showing most SPs had received training in the last 2 years at 57.9% (n=38)
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Graph 5.2

Identifying the training needs that the SPs feel they require.
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Table 5.2

Training needs as identified by SP’s

Identified training Needs

%

Number

Non identified

45.6%

31

Interviewing techniques

10.3%

7

Training of trainers

8.8%

6

Smoking Cessation for youth

7.4%

5

health

7.4%

5

Facilitation skills

4.4%

3

Certified SCT

4.4%

3

Information on Champix

2.9%

2

Clinical supervision

2.9%

2

Maudseley training

2.9%

2

Multiple addictions

1.5%

1

Intensive smoking cessation

1.5%

1

Smoking Cessation for mental

The top training needs identified were, 10.3% (7) of SP’s felt they needed further training
in interviewing techniques and 8.8% (6) felt they needed to learn more on how to deliver
further training to smoking cessation trainers.
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5.2.3

Professional Background of service providers:

Graph 5.3

The spread of professional backgrounds of SPs
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Table 5.3

Showing professional background of SP’s

Professional
Background

%

Number

Nurse

71.2%

47

Health Promotion

19.7%

13

Community Worker

1.5%

1

Medical Doctor

1.5%

1

Physiotherapy

1.5%

1

Pharmacy

1.5%

1

Environmental Health

1.5%

1

Addictions Counsellor

1.5%

1

100.0%

66

Total

The top 2 professional backgrounds for cessation service providers were:
71.2% (n=47) Nurse and 19.7% (n=13) Health Promotion.

81

5.2.4

Service availability

Graph 5.4

Populations to whom the cessation services declared they were available

Table 5.4

Populations to whom the cessation services declared they were available.

Populations to whom services
available

%

Number

All Population Groups

42.9%

27

In patient /Staff and Community

23.8%

15

Out Patient/Staff & Community

20.6%

13

In Patient/Out Patient and Staff

7.9%

5

Out Patient & Community

3.2%

2

In Patient and Staff

1.6%

1
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The top 3 population groups served by cessation providers were:
42.9% (27) All population groups
23.8% (15) In patient/staff & community
20.6% (13) Out patient/staff & community
There was only one cessation service that said they were exclusively for the use of
inpatients and staff.

5.2.5

Services provided

It was known that both telephone, one to one and group therapy was being offered but to
what degree was not known.

Graph 5.5

Types of services provided
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Table 5.5

Types of smoking cessation services provided.

Types of Service Provided

Frequency

%

Individual advice &
Counselling

62

98.4%

Group Advice

39

61.9%

Telephone Advice

57

90.5%

Almost all of the 68 respondents provided individual advice & counselling and telephone
support but only 61.9% (n=39) provide group advice or counselling.

5.2.6

Duration of consultations:

Initial individual sessions showed a mean duration of 40 min (range 10 -90mins).
Individual review sessions showed a mean duration of 23 min (range 5–60mins).
60% (n=38) provided individual support on a weekly basis.
Initial telephone sessions had a mean duration of 15 min and review sessions with a mean
duration of 6 min.

5.2.7

Patient follow up:

There was not a standardised follow up identified, other than by the North Western region
which represents 9.5% of the country’s smoking cessation services.
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Graph 5.6

How many providers follow up patients?

57.1% (n=36) follow up all patients, 38.1% (n=24) follow up some patients (*specifically
those who have set a quit date), while only 4.8% (n=3) do not follow up any individuals.
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How service providers set out their planned review of patients attending a smoking
cessation service:
Graph 5.7

Schedule of follow up contacts with patients:

Table 5.6

Schedule of patient follow up visits

Follow up schedules

%

Frequency

2 Week follow up

54.8%

34

1 Month Follow up

48.4%

30

3 Month follow up

75.8%

47

6 Month follow up

45.2%

28

1 Year follow up

69.4%

43

Most common follow ups are conducted at 2 weeks 50% (34), 3 months 75.8% (47) and 1
year 69.4% (43).
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5.2.8 Use of CO monitor as a means of validating quit status of patients:
Graph 5.8

Number of providers who use CO as a means of validating quit status

Table 5.7

Frequency of CO Validation by SP’s

Frequency of CO Validation

%

Frequency

Never

27.0%

17

Rarely

12.7%

8

Sometimes

23.8%

15

Often

15.9%

10

Always

20.6%

13

Total

100%

63



27% (17) Never use CO validation.



36.5% (23) Rarely or sometimes use CO validation.



36.5% (23) Use it often or always.
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5.2.9

Geographical spread of services

Graph 5.9

Regional spread of hours of cessation service per week
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Table 5.8

Hours of service per week in the different regions
No. of

No.

Proportion of

Responses

hours/week

total hours/week

Dublin

17

212.5

20.10%

Rest of Leinster

20

231

21.90%

Connaught

7

80

7.70%

Ulster

13

260.1

24.60%

Munster

15

175

16.70%

1

98

9.00%

72

1056.6

100.00%

Province/Region

No region
identified
Totals

Shows the distribution of services throughout the country in hours delivered. The service
in Dublin and the rest of Leinster represents 41% of the total hours of service reported in
this survey (Currie et al., 2010).
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5.2.10
Graph 5.10

Setting of smoking cessation services
Setting of smoking cessation services.
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Table 5.9

Where cessation services are delivered

Setting of Service
General Hospitals

%

Frequency

41.3%

26

Psychiatric Hospitals

1.6%

1

Maternity Hospitals

4.8%

3

G.P. Surgeries

12.7%

8

Other Primary Care settings

12.7%

8

4.5%

3

20.6%

13

Community Centres

9.5%

6

Care of the Elderly

7.9%

5

25.4%

16

Pharmacies
Health Centres

Other settings

47.7% (30) hours are hospital based. There was only 1 psychiatric hospital identified as
having a service.
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5.2.11

Computer accessibility and data collection:

Graph 5.11

How many service providers have access to computers?

Almost 1/3rd of service providers 31.7% (19) have no access to a computer.
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5.2.12

Data collection and analysis

Graph 5.12

Data collected by service providers and whether it was analysed or not.

A surprisingly large amount of data is collected by service providers and is not being
reported on or analysed. The largest amounts of unanalysed/unreported data collected are:
Smoking frequency 57.8% (37) and number of previous quit attempts 53.1% (34) but even
routine data such as age 39.1% (25) and gender 40.6% (26) are left unanalysed.
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5.3

Smoking cessation treatment database

5.3.1

Sample

49 service providers agreed to participate in the pilot use of the newly developed treatment
database. Using this database a 3 month study was conducted of patients recruited crosssectionally while attending the 49 participating smoking cessation services throughout
Ireland. 41 completed databases were received, 2 of which were not included as they were
not suitable for analysis, the data was collected in an Access database and not in the
specially developed Excel based database. It was not possible to match the data fields that
these 2 providers collected in their own existing Access database as they differed too much
from those set out in the piloted treatment database. A total of 1,490 patients were
recruited and subsequently analysed from the remaining 39 databases received. A number
of written and phone requests to the outstanding 8 service providers were made to no avail.
This gave a response rate of almost 84%.

5.3.2

Subject demographics

Of the 1490 patients entered into the treatment database there was a fairly even gender split
with 736 Females and 752 males treated, gender data was missing on 2 patients this gender
split is in keeping with the statistics from the 2011 national census.

94

Graph 5.13

Males (n=752) Females (n=736) and total number of patients analysed.

(n=1488)
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Graph 5.14

Age distribution of the study subjects (n=1402).

From a total of 1402 patients whose age was recorded this graph shows the spread of the
age ranges captured during the 3 month pilot of the treatment database. Age was missing or
incorrectly entered on 88 patients. The majority of patients were between 46 and 65 years
of age.

5.3.3

The overall quit rates recorded in the treatment database.

Quit rates were recorded at 4 weeks and 3 months using the Russell Standard definition of
quit, a patient was considered to have quit at 4 weeks if they were assessed (face to face, by
postal questionnaire or by telephone) 4 weeks after their quit date and declared that they
had not smoked a single puff on a cigarette in the past 2 weeks.
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A patient was considered to have quit at 3 months if they were assessed (face to face, by
postal questionnaire or by telephone) 3 months after their quit date and declared that they
had not smoked more than 5 cigarettes in the past 10 weeks.

Graph 5.15

Quit rate (%) of all patients entered

Table 5.10

Quit rate results at 4 weeks and 3 months
Frequency

Frequency

Quit

%

Not Quit

%

4 Weeks

552

37%

936

62.8

3 months

334

22.4%

1151

77.3

The overall quit rates of those who attended for smoking cessation treatment regardless of
setting a quit date, were 37% at 4 weeks and this rate fell to 22.4% at 3 months.
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5.3.4

Setting of quit date

Not all patients attending a service set a quit date. Some may only be contemplating
quitting and need to be motivated and helped in preparing for their quit attempt. This next
graph demonstrates how important it is to progress patients to this stage.
Quit rates (%) amongst those who had set a quit date (n=890) compared
to those who did not set a quit date (n=600).
Graph 5.16

2 = 545.372a, (2) P < 0.05 at 4 weeks
2 = 200.809a, (2) P < 0.05 at 3 months
61% of patients who set a quit date (n=890) were quit at 4 weeks. This fell to 35% at 3
months. Of those who did not set a quit date (n=600) there were 1.4% quit at 4 weeks and
3.8% quit at 3 months.
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Graph 5.17

Quit rates according to age ranges (n=1402) at 4 weeks and 3 months

2 = 14.359a, (6) P = 0.053 at 4 weeks
2 = 38.221a, (6), P < 0.05 at 3 months
Table 5.11

Numbers of quit rates recorded within age ranges

Data on age range Quit at

Number

%

4 weeks

1402

94.1

3 Month

1401

94

Showing quit rates by age demonstrates that the older age groups are statistically more
likely to quit than their younger counterparts at 3 Months. The quit rate in all age groups
falls from 4 weeks to 3 months.
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Graph 5.18

Quit rates according to age and gender

2 = 14.102a, (2), P < 0.05 at 4 weeks.
2 = 7.958a, (2), P < 0.05 at 3 Months.
Graph 5.18 shows quit rates at 4 weeks to be 41.8% of Males and 32.4% of Females falling
to 25.3.5% and 19.7% respectively at 3 months, showing that males have significantly
higher quit rates compared to female quit rates in the study population for both time
periods- 4 week and 3 months.
5.3.4

Smoking history

The number of cigarettes smoked per day and the Fagerstrom score were calculated and
scored 0-3 low addiction, 4-5 medium addiction and 6-10 high addiction in order to
determine the degree of addiction of each patient.
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Number of cigarettes smoked daily:
Out of a total of 1,436 patients whose daily smoking rate was recorded, 400 (27.9%)
reported smoking less than 20 per day, while 1036 (72.1%) patients reported smoking more
than 20 per day. While the exact number of cigarettes smoked per day was recorded for
analysis they were divided into 5 different categories; 0-10, 11-19, 20-29, 30- 39 and 40+.

Graph 5.19

Breakdown of number of cigarettes smoked by patients within the

dataset
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Table 5.12

Numbers of cigarettes smoked per day

Numbers smoked per day

Frequency

%

0 to 10 cigs per day

213

14.8

11 to 19 cigs per day

187

13.0

20 to 29 cigs per day

656

45.7

30 to 40 cigs per day

221

15.4

40 plus cigs per day

159

11.1

Total

1436

100.0

Quit rates within number of cigarettes smoked.
Graph 5.20

Quit rates according to number of daily cigarettes smoked

2 = 8.452 (8), P = 0.391 at 4 weeks
2 = 15.244 (8), P < 0.05 at 3 months
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Quit rates according to number of cigarettes smoked by individuals was statistically
significant at 3 months: heavier smokers were shown to be more likely to remain quit at 3
months 25.2% (n=159) than lighter smokers 22.2% (n=400)

Fagerstrom score
The addiction level of the smoker was recorded by calculating their Fagerstrom score. This
was recorded in 1440 of the 1490 patients entered. This did not prove to be a statistically
significant predictor of quit rates.

Graph 5.21

Distribution of the Fagerstrom scores across the patient population in

the dataset.
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Table 5.13

Fagerstrom

Recording of Fagerstrom score

Numbers

%

0-3

290

20.1

4-5

428

29.7

6-10

722

50.1

Total

1440

100

Scores

The largest portion of the dataset had a high Fagerstrom score of 6-10 @ 50 % (n=722)
demonstrating a high level of tobacco dependency.

Graph 5.22

Quit rates according to Fagerstrom scores
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The quit rates according to the patients Fagerstrom score: while the results are not
statistically significant it does show a trend for the higher the degree of dependency the
lower the quit rate.
2 =8.566a, (4), P = .073 at 4 weeks.
2 =6.905a, (4), P = .141 at 3 Months.

5.3.5 Social class/ occupation

The entire population was classified into one of the following social class groups which are
defined on the basis of occupation:
1. Professional worker
2. Managerial and technical
3. Non manual
4. Skilled manual
5. Semi-skilled
6. Unskilled
7. All others gainfully occupied and unknown is used where no precise allocation is
possible.
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Graph 5.23

Social class/occupation groups within the dataset

Table 5.14

Social classes within the dataset.

Social class/occupation

Frequency

%

Professional Worker

41

2.8

Managerial & Technical

115

7.9

Non Manual

237

16.3

Skilled Manual

292

20.1

Semi-Skilled

271

18.6

Unskilled

264

18.2

All Others

234

16.1

Total

1454

100
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Graph 5.24

Quit Rates (%) by Social Class/Occupation (n=1454)

Quit rates by occupation was shown to be statistically associated with quit rate at 4 weeks
and 3 months.
2 =49.668a (12), P <0.05 at 4 weeks.
2 =34.296a (12), P <0.05 at 3 months.
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Table 5.15

Quit rates within SE groups

SE Groups

Total within

Quit at 4

Quit at 3

each group

weeks

months

Professional Worker

41

13

10

Technical

115

61

42

Non Manual

237

88

57

Skilled Manual

292

125

79

Semi-Skilled

271

121

64

Unskilled

264

77

45

All Others

234

58

31

Total

1454

543

328

Managerial &

When these were grouped into SE groups 1-3 this demonstrated quit rates of 41% at 4
weeks and 28% at 3 months while SE groups 4-6 demonstrated quit rates of 39% at 4
weeks and 23% at 3 months.
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5.3.6

Patients primary motivation to quit

Graph 5.25

Patient’s primary motivation to quit in the dataset. (n=1425)
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Table 5.16

Patients Primary motivation to quit.

Primary Motivation to
Quit

%

Number

Current Illness

27%

378

Financial Gain

2%

31

Pregnant

6%

90

Freedom from Habit

4%

53

Family/Children

3%

49

Medical Advice

9%

146

Health Gain

43%

607

Improve Quality of Life

4%

60

Other

1%

11

Total

100%

1425

Health was overwhelmingly the primary motivation to quit smoking at 69.1% (985)
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Graph 5.26

Quit rates according to Primary reason for quitting

2 =44.564a (16), P < 0.05 at 4 weeks.
2 =22.956a (16), P = 0.115 at 3 Months
Primary motivation for quitting is statistically significant at 4 weeks but does not seem to
be a factor in maintaining abstinence at 3 months most notably in the motivation of
‘financial gain’ which had a quit rate of 38.7% at 4 weeks and only 12.9% at 3 months.
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5.3.7

Pregnancy

118 patients entered into the database were reported as pregnant which represents 15.6% of
the total female numbers.
Graph 5.27

Number of pregnant and non-pregnant women within the dataset.

Table 5.17

Pregnant and non-pregnant women.

Pregnant

Frequency

%

No

634

84.3

Yes

118

15.6

Total

752

100
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Graph 5.28

Showing quit rates amongst pregnant and non-pregnant women.

2 = 15.485 (2), P < 0.05 at 4 weeks.
2 = 7.054 (2), P < 0.05 at 3 months.
Of the 118 pregnant women the quit rate was 16.5% at both 4 weeks and at 3 months. This
compares with 35.2% at 4 weeks and 20.3% at 3 months of the non-pregnant female
population in the study.
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5.3.8

Graph 5.29

Table 5.18

Quit rates by quitting method:

Methods used to aid quit attempt.

Treatment methods used

Method Used

Number

%

Cessation programme

284

32%

CP+NRT

458

51%

CP & Combination therapy

11

1%

CP+Zyban

1

0%

CP+Champix

137

15%

Total

891

100%
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The most often used method by this cohort was smoking cessation treatment programme
accompanied by nicotine replacement therapy in 52% (469) of the patients recorded.
Graph 5.30

Quit rates according to methods used

2 = 8.925a (8), P = .349 at 4 weeks.
2 = 8.055a (8), P = .428 at 3 months.
Quit rates using cessation programme only and cessation programme plus NRT fall off by a
significant 33% and 30% respectively whereas the quit rate of those treated with Champix
and cessation programme remained at 65% at both 4 weeks and 3 months. The above data
represents results of 891 of the total 1490 patients entered into the data base.

The

remaining 599 who failed to return and commence treatment were reported as a failed quit
attempt in the overall quit rates reported in this thesis which was 37% at 4 weeks and 22%
at 3 months. The quit date of those that had set a quit date and therefore commenced
treatment, had a quit rate of 61% at 4 weeks and 35% at 3 months.
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5.3.9 Quit rates according to number of previous quit attempts
Graph 5.31

Table 5.19

Number of previous quit attempts by patients in the dataset

Number of previous quit attempts.

Previous quit attempts

Frequency

%

Never

334

23.2

≤3

827

57.6

4 to 10

243

16.9

>10

33

2.3

Total

1437

100

The most commonly reported number of previous quit attempts
was ≤3 at 57.6%(827)
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Graph 5.32

Quit rates (%) by previous number of previous quit attempts

2 = 17.834a (6), P <0.05 at 4 weeks.
2 = 9.755a (6), P = .135 at 3 months.

When looking at the number of previous quit attempts the trend was for the more
previous quit attempts the patients had the more likely they were to have a successful quit
attempt at 4 weeks however this did not reach a statistically significant level at 3 months.
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5.3.10

Reporting/validation of quit status

CO validation of quit status was missing on 867 patients in the dataset at 4 weeks and in
1092 patients at 3 months.
Graph 5.33

Reporting methods of quit status at 4 weeks and 3 months

Most validations of quit status are by self-reporting 68% (427) at 4 weeks and 80% (320) at
3 months.
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5.3.11

Patient Status on referral

The distribution of where patients were seen and whether they were treated as an inpatient
or an outpatient in the dataset are described below.
Graph 5.34

Patient status on referral

Table 5.20

Patient status

Patient Status

Frequency

%

In Patient

620

41.7

Out Patient

322

21.7

Day Patient

22

1.5

Public/Community

413

27.8

Staff Members

86

5.8

Mental Health

24

1.6

1487

100

Total

119

Graph 5.35

Patient status and their quitting rates at 4 weeks and 3 months

2 = 33.212a (10), P < 0 .05 at 4 weeks.
2 = 14.306a (10), P = .159 at 3 months.
Where patients were at the time of being treated was seen to be statistically significant in
terms of quit rates at 4 weeks but not at 3 months. In the case of inpatients the quit rate fell
from 40% at 4 weeks to 24% at 3 months.
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5.3.12

Graph 5.36

Referral source

Referral sources of patients in the dataset
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Table 5.21

Referral source of patients

Referred by

Frequency

%

Self

362

24.5

Hospital Doctor

256

17.3

Nurse/Midwife

697

47.2

GP/Pharmacist

97

6.6

Practice Nurse

4

0.3

Quitline

8

0.5

Mental Health Service

13

0.9

Other

39

2.6

Total

1476

100

Neither the national Quitline nor practice nurses seem to refer patients to specialist
cessation services on a regular basis and given the sample size of 1476 GP’s only referred
6.6% of patients.

122

Graph 5.37

Patient referral sources and their respective quit rates at 4 weeks and 3

months.

2 = 14.531a (16), P = .559 at 4 weeks.
2 = 14.359a (16), P = .572 at 3 months.
Referral sources are varied and the success rate of the patients quit attempt is not shown to
be more statistically successful in any category. Self-referrals do have the highest quit rate
at over 40% at 4 weeks, however they do have the biggest drop in quit rates measured at 3
months.
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5.3.13

Statistically associated covariates.

Certain covariates were found to be statistically associated with quit rates. The following
data were collected to demonstrate whether they had any bearing on quit rates at 4 weeks
and 3 months.
Table 5.22

Statistically associated covariates/factors influencing quit rates.

Trends shown here were not statistically associated with quit rates however it shows a
relationship with quit rates going in the one direction for example the higher the
Fagerstrom score of patients the lower their quit rates and this may become statistically
significant if numbers were greater and patients were followed for a longer period of time.
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5.4

Patient satisfaction questionnaire:

All data were inputted on a master Excel spread sheet from all completed patient
satisfaction questionnaires received from patients of each of the 41 Smoking Cessation
service providers.
A total of 342 patients returned completed patient satisfaction questionnaires having
availed of smoking cessation services during the 3 month pilot of the Data Collection
Instrument (Patient treatment database).
Of the 342 patients, all were above 18 years of age. Almost half were 18-35 years of age
and 172 were females.

5.4.1 Patient demographics

Graph 5.38

Patient satisfaction gender distribution: Male 44.5% (138) Female

55.5% (172)
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Table 5.23

Numbers of Males and Females in the survey
Gender

Frequency

%

Male

138

44.5

Female

172

55.5

Total

310

100

The data presented a reasonably even split between males and females (CSO 2011 census F
49.9% and M 50.6%). There was gender data missing on 9.4% of the completed
questionnaires.

5.4.2

Patient preferences for day and time of service.

The majority preferred weekdays to weekends and also morning hours for seeking advice.
Less than 7% of the patients had to wait for more than 4 weeks for an appointment with the
smoking cessation service.
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Graph 5.39

Patients appointment preference weekends or weekdays

Table 5. 24

Weekday/Weekend preference

Preference

Frequency

%

Weekends

79

23.9

Weekdays

252

76.1

Total

331

100
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Graph 5.40

Preference for time of day of service

Table 5.25

Patients preferences of appointment times
Frequency

%

Mornings

165

49.4

Afternoons

65

19.6

Evenings

103

31.0

Total

332

100.0

Preference for Time

The majority of patients 49% (164) preferred their appointments to be held in the mornings
while 31% (103) preferred evening clinics and the least popular time was afternoons which
was preferred by only 19% (65) of patients.
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5.4.3 Length of time awaiting appointment
Graph 5.41

Waiting time for appointments

Waiting time for appointments was divided up into 4 groups <1 week 1-2 weeks, 2-4 weeks
and ‘don’t know’ category to allow for those whose appointments were made on their
behalf by others.
The results show that the waiting time for appointments was extremely short at less than 1
week for almost 44.6% (146) of patients while only 14.1%(46) were waiting from 2 to 4
weeks for an appointment.
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5.4.4 Payment for prescriptions

Graph 5.42

Numbers reporting having to pay for prescriptions

Table 5.26

Number of patients paying for prescriptions

Numbers having to pay

Number

%

Yes

101

33.0

No

130

42.5

Nothing prescribed

75

24.5

Total

306

100.0

for prescriptions
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Graph 5.43

If paying for prescriptions influenced participation in the treatment

programme

Table 5.27

Whether payment influenced treatment

Did payment influence

Frequency

%

Yes

21

7

No

76

25

Not applicable

205

68

Total

302

100.0

treatment

When asked whether having to pay for prescriptions influenced their participation in the
smoking cessation treatment programme, of those that responded, over 25% (76) said it did
not, whereas only 7% (21) reported that it did.
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5.4.5 Willingness to return to the service.

Graph 5.44

Patients willingness to return to the service

Over 94% (283) of the patients reported that they would be happy to return to the service
again should they require it.
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CHAPTER 6

DISCUSSION

This is the most comprehensive and first independent evaluation of the smoking cessation
services (SCS) in Ireland. EC funded projects such as PESCE and eSCCAN have looked at
aspects of SCS in a number of other EU countries and the UK publishes regular reports on
its services. It is clear from these projects and the EQUIPP report that there is no agreed
‘best’ approach but there are lessons to be learned from studying the different approaches.
I will discuss the relevant aspects from the Census Questionnaire, Treatment database and
Patient satisfaction questionnaire separately.

6.1

Census questionnaire

6.1.1 Cessation specialists
The Irish services are most like England and Northern Ireland but are much less well
developed or funded.
It was established from the census that the majority of cessation specialists were nurses
(71.2%) similar to Northern Ireland and England but very different from many EU
countries such as Germany where psychiatrists and psychologists are the main cessation
specialists, or Spain Greece and Denmark where respiratory physicians are most often
associated with treatment of tobacco dependence. France and Belgium have special
‘tobaccologists’ who come from a variety of healthcare specialities (EQUIPP, 2011).
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6.1.2 Training of specialist smoking cessation service providers

All the specialists had smoking cessation training and the majority (58%) had had training
in the previous 2 years. It is clear from the survey that the SPs are very conscious of the
need and importance of continuous further training and also their willingness to participate
where 62% identified further training as a priority.
There is no agreed standard of training required or accreditation demanded for the
practicing as a smoking cessation specialist in Ireland. None of the SPs had degree level
qualification in SC. At present there is no formal accreditation in many EU countries but
the ENSP is trying to get consensus across the EU. France, Belgium and the Netherlands
have a registration process.

6.1.3 Service aspects

A noticeable aspect of the activities of the SPs was that very few of them were full-time SC
practitioners with 43% giving less than 10 hrs. per week to the activity. Again this is not
unusual in Europe but is not the norm in the UK. Most services were located in hospital
facilities and most patients came from hospital services. 42.9% of the services were
available to all population groups but some services limited their availability to their own
hospital populations (in patient/outpatient and staff) 7.9 %.
Before this study there was no national database for collection of smoking cessation
statistics. Information and statistics on SCS was collected, mostly manually, by individual
practitioners and reported for administrative purposes to a health board manager. What we
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found was that the data collected was not always adequate for monitoring the service but
also that no systematic use was made of the data collected to assess the service. Also much
of the data collected was not analysed or used for any discernible purpose. For example,
data on pregnancy status (32.8%), age (39.1%), gender (40.6%), number of previous quit
attempts (53.1%), smoking history (57.8%), Fagerstrom score (37.5%) and patient status
(25%) were collected by SPs and but no further attention or use of the data was uncovered.
Asking SPs to collect data and not to use it, or give the SPs feedback on their service, can
only be seen as a poor incentive for them to continue to collect, or indeed expand on the
data collected.
The adequacy of the resource allocated to smoking cessation is difficult to assess but using
NICE guidelines where it is recommend that services should be available to treat some 5%
of smokers per year; this is probably not being met in Ireland. It is also obvious that the
distribution of services throughout the country is uneven even when allowance is made for
distribution of smokers.
The difficulty of providing SC services in sparsely populated areas, as in most specialised
healthcare services, is also evident.
The structure of the service offered also varied greatly. This was particularly noticeable in
scheduling of services where there was a complete lack of uniformity in the periodicity of
follow up of patients. Only the North Western region which represents 9.5% of service
providers have a standardised follow-up regime consisting of a weekly review for the first 4
weeks, fortnightly up to 3 months and then monthly for up to 1 year. This is more than
recommended by NICE but contrasts with other Irish services where it was found that
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currently only 47.6% of respondents follow up patients 4 weeks post their quit date 40.0%
of whom report using CO monitoring to validate quit status often or always.
NICE guidelines suggest:


SC services should aim to treat at least 5.0% of the estimated population of people who
smoke each year.



That intensive support should be offered to smokers who would like to quit in weekly
sessions for at least the first 4 weeks following a quit attempt.



SC services should aim for a 35% 4-week success rate validated by CO monitoring, with
success defined as not having smoked in the third and fourth weeks following the quit date.
This survey showed that almost a third of smoking cessation service providers did not have
access to computers. This highlights the need for improvement in this area in both training
of data capturing as well as financial input in developing services and implementing proper
and uniform data collection systems throughout the country.

6.2

Treatment database

6.2.1 Quit rates.

While this study was not undertaken to study the outcomes of the services in terms of
success rate in quitting, it is clear from the data collected that the results at one and three
months are in line with some international outcomes but lower than NHS in UK (NICE,
2008). However more comprehensive studies of longer duration would be needed to
confirm these findings.
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6.2.2 Gender differences in quit rates

Gender results showed that across all age groups a higher number of men were successful
in quitting smoking than women, and the older age groups were more likely to be
successful at quitting than their younger counterparts. This is also in line with international
experience. A study in 2003 found that women appear to have higher behavioural and
lower nicotine dependence than men; therefore both nicotine and behavioural treatment
should be tailored to women to increase their chances of abstinence (Bohadana et al.,
2003).

6.2.3 Pregnancy:

Pregnant women (n=118) were compared with non-pregnant women. The quit rates of
pregnant women at 4 weeks was 16.5% compared with 35.2% of non-pregnant women.
The findings within pregnant women were surprising in that the quit rates achieved by them
were disappointing. The expectation was that their motivation to quit would be high.
At 3 months the quit rate of pregnant women remained at 16.5% whereas their nonpregnant counterparts quit rates fell. It could perhaps be deduced from this that if a
pregnant woman is successful at stopping she is more likely to stay quit longer. This would
need further research in that the stage of pregnancy is not collected in this data set and so it
could be that they only remained quit while pregnant. Nevertheless, is poses interesting
questions and could indicate further worthwhile rationale in targeting women while
pregnant, with a view to bringing down the overall smoking prevalence in women.
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It

would also be interesting to see whether this would last beyond the term of their pregnancy.
Pregnant women in the UK tend to be dependant smokers often with limited resources (Lee
et al., 2006) which could be a reason for their disappointing quit rates if this was also
shown to be true in Ireland. Counselling from a smoking cessation specialist together with
written support materials is effective in aiding the smoking cessation of pregnant women.
Studies show that specialist support enables about one in 15 to stop smoking for the
remainder of the pregnancy who would not otherwise have done so (West et al., 2000).
The poor results may result from a paucity of services in Ireland for this population group.

6.2.4 CO validation of quit status:

The quit status of patients was validated by CO monitor reading done at 4 weeks on 188
patients, which means that 427 patients who reported being quit at 4 weeks did not have
their quit status validated. The number of cessation officers who reported CO validation in
the census was 40%. The number of services using CO validation in the database was 20
out of 39, which represents over 50% of those who participated. Perhaps being involved in
completing a database on a national level will increase reporting and therefore give rise to
more valid and realistic results.

6.4.5 Setting of quit date:

The importance of setting a quit date is underlined by the fact that the quit rates amongst
this specific group at 4 weeks was 61% and 35% at 3 months whereas overall quit rates
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were 37% and 22% respectively. Planning commitments and setting of a quit date has been
shown to play an important role in smoking cessation. Successful quit attempts have been
shown to be markedly higher amongst those with a set quit date. (Balmford et al., 2010).

6.4.7 Patient status

This was broken into several categories, such as out-patients, in-patients, staff members,
community care etc., and it was a statistically associated with quit rates at 4 weeks but not
at 3 months. The result was highest for staff members and this could perhaps be explained
by motivation from working within the health sector and proximity to the service.

6.4.8 Referral source

This was not shown to be a statistically significant predictor of quit rates. There were
notably few referrals from the national Quitline or practice nurses to specialist cessation
services. This should be encouraged as the chances of quitting are approximately doubled
with group therapy compared to being given self-help materials without face-to face
instruction and support (EQUIPP, 2011).

6.4.9 Number of previous quit attempts

The higher the number of previous quit attempts reported by patients was shown to be a
predictor of quit rates at 4 weeks but not so at 3 months in line with recent international
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literature (Jardin and Carpenter, 2012). Therefore when dealing with these patients’ greater
efforts should be made to prevent relapse, perhaps by longer and more frequent follow up.

6.4.10

Type of treatments

The data showed that patients who received counselling plus a combination of NRT were
the most successful group, however those that received both counselling and Champix were
more likely to be successful at 3 months, although the numbers in this particular group were
very small and further data needs to be collected in this area. The least successful group
were those who received counselling alone. The results with regard to types of treatment
received, on quit rates was not statistically significant, probably because of sample size but
shows a trend towards more support and pharmacotherapy being associated with higher quit
rates. International results show that current pharmacological treatments are effective, and
estimates are that the abstinence rate at 6 months among adults randomly assigned placebo
was about 16% versus 19 to 26% across most pharmacotherapies, in contrast use of
varenicline and combination NRT were associated with rates of 33% and 37% respectively
(Fiore et al NEJM Sept 2011).
There are at present no published set of smoking cessation guidelines in Ireland. The
National Tobacco Control Framework sets out the strategic direction for Tobacco Control
for the next 5yrs from 2011. An annual implementation plan will be developed, best
practice guidelines for the management of tobacco in mental health settings have been
developed but these are not smoking cessation guidelines (EQUIPP).

The HSE has

developed a national standardised model for delivering training in Brief Intervention skills
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for Smoking Cessation. This training programme is guided by the HSE Tobacco Control
Framework Document 2010 and incorporates the WHO recommendations of the MPOWER
model for tobacco control. The implementation of this programme is vital for the success of
an expansion of cessation services both because it is known that brief intervention works in
getting people to stop smoking but also health care staff trained in brief intervention are
also more likely to refer to more successful comprehensive treatment services.

6.5

Patient satisfaction

This is the first study in Ireland to provide baseline information on patients’ satisfaction on
the currently available smoking cessation services in the four HSE areas in Ireland.
Overwhelmingly more than 80% of patients were satisfied with the current service
including training of staff, time and location of service and a similar number would also
recommend these services to friends and family. This is a great tribute to the dedication and
professionalism of the individual practitioners who provide the smoking cessation service.

Having data like this from across the country will enable us to better design and target
services suitable for different population groups. More such surveys are needed to help
with better design and delivery of the much needed service. It is important that the
cessation service needs in Ireland are properly addressed, as a cost-effective comprehensive
tobacco dependence treatment program can accelerate further declines in smoking rates
(Currie et al., 2012).
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CHAPTER 7

7.1

STUDY LIMITATIONS AND CONCLUSIONS

Limitations

7.1.1 Census questionnaire:

This is a novel questionnaire, purpose built and therefore may not capture all important data
but was piloted internally and among a sample of the target population of service providers.
The lack of access to computers of some of the respondents was surprising and added to
delay and incompleteness.

7.1.2 Treatment database

Only 49 service providers out of a total of 63 identified in the initial database of service
providers agreed to pilot the treatment database. Others were not in a position to participate
in the project and of the 49 that agreed 39 datasets were suitable for analysis.
Data was collected only over a 3 month period and so there were are no seasonal aspects of
cessation rates been shown.
Although exhaled CO monitoring was recommended the majority of smokers self-reported
their smoking status and this gives rise to uncertainty about the validity of quit rates.
More than 95% of the population studied was Caucasian in origin and therefore ethnicity as
a contributor to disparities in smoking cessation cannot be applied.
Reporting of Number of Cigarettes smoked was not always accurate, in that some cessation
providers recorded 0 as their patients had quit that day, or within a week or so of attending
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the service and so when analysing the level of smoking as a predictor of quitting this may
have caused anomalies. In future, clearer guidelines should be given to service providers
on completing the Fagerstrom score and number of cigarettes smoked, so that the patients’
average numbers of cigarettes smoked when they were smoking is what should be recorded.
While the number of cigarettes smoked was found to be a statistically significant predictor
at 3 months, its significance may be even greater if recorded correctly and not underreported by service providers as was the case in this project. As well as a predictor of quit
rates it could also help as a determinant of the treatment offered to the patients.

7.1.3 Patient satisfaction survey:

The number of patients who returned completed survey questionnaires was relatively small
at 342 out of 1490 patients who were entered into the treatment programme, during the 3
month pilot of the treatment database.
This may be because of time constraints of the service providers, who may not have
stressed its importance, their lack of administrative support, as well as the lack of
motivation of patients to complete and return the forms. Although it was explained in great
length the anonymity of patients and the fact that completed forms would not be returned to
their service provider they still may have had doubts or reservations about expressing their
opinions to colleagues of their careers. Nevertheless the insight gained is worthwhile.

143

7.2

Conclusions

The conclusions of this study are as follows:

7.2.1 Database of cessation service providers

No up to date comprehensive database of service providers and their contact details for
circulation to health professionals to aid referrals existed.

7.2.2 Census of smoking cessation services

Only 1 smoking cessation service clinic was identified in a psychiatric setting.
No standardised procedure for follow up of patients is being practiced.
71% of Cessation SPs were from nursing background.
Poor data collection, almost 1/3rd (32%) of SPs do not have access to a computer.
Poor use is being made of the data collected.
No standardised training is being given to cessation service providers, 61% identified
further training as a priority.
Patients who attended the services are very happy with them and 94% said that they would
be willing to return.
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7.2.3 Smoking cessation treatment database

This study has demonstrated that quit rates achieved by the present services are 37% at 4
weeks and 22.4% at 3 months. However amongst pregnant women the quit rates were low
at 16%. It demonstrated consistently poor outcomes in known vulnerable subgroups of
smokers such as youth, hard core smokers, pregnant women and those from lower SE
groups. It also showed that referrals from sources outside of the cessation services and
hospitals were low, as is the case in the UK, where GPs are the main referral source but still
their referrals are low in number (McRobbie et al., 2008).
Men had a higher quit rate than women in this study, in keeping with the results of a metaanalysis of NHS cessation services in the UK in 2010 (Bauld et al., 2010).

7.3.4 Patient satisfaction

Having received and analysed responses from 342 patients who used the services, although
a small number, it gives us better insight into their needs, likes and dislikes. It helps us to
dispel ideas that perhaps patients would not be prepared to pay for their prescriptions in
order to part take in a tobacco dependence treatment programme. It also demonstrated
quite clearly, that the time of day preferred by patients was mornings, weekdays and not
weekends or afternoons. After looking at the 33% who did have to pay for prescriptions
they overwhelmingly (78.1%) reported that it did not interfere with their participation in the
treatment programme.
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Overall therefore, this study shows that there are Smoking Cessation Services available
throughout the country, that all service providers have basic training and that there is
widespread patient satisfaction with the services on offer. The results at 3 months are
satisfactory but below expectations in the UK (NICE, 2008). It also shows the need for
monitoring and recording of smoking cessation activity, in order to properly evaluate fully
its effectiveness and provide the evidence base to improve and further develop treatment
programmes of this sinister disease.
In order to address health inequalities smoking cessation services need to be available to all
members of society both in rural and urban areas. Particular attention should be given to
maternity and psychiatric treatment centres and areas with high levels of low socioeconomic classes. This study also shows the lack of uniformity in treatment services,
training of SPs and monitoring of the service outcomes and highlights the need for
significant changes.
Although there is no agreed standard of care in Europe it is clear that the training of
practitioners, the availability of services, the monitoring of activity and outcomes leaves
much to be desired.
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CHAPTER 8

RECOMMENDATIONS

Based on the conclusions from this study the following recommendations emerge:

8.1

Training

1. That the training of smoking cessation practitioners be formalised with a requirement to
achieve at least diploma level and higher level training at degree level needed for
advancement.
2. That an accreditation system is introduced and continuous professional development be
formalised and regulated.
3. Training for health professionals is needed to encourage them to refer smokers to
specialist clinics.

8.2

Services

1. The elements of a standardised service should be agreed between relevant stakeholders
including service providers, managers, smokers and the funding agency.
2. That guidelines for best practice are developed and introduced and an electronic
database be established at national level with routine monitoring of activity and
outcomes.
3. There should be more frequent interaction with representatives of identified groups with
high prevalence or special problems such as mental health groups, unemployed,
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maternity services, poverty groups and youth organisations.

Services should be

specifically targeted towards these vulnerable groups and those in lower SE categories
who have limited resources and access to services.
4. That a standardised service be available to all smokers presenting for treatment at any
cessation clinic in the country.
5. That there be increased availability and access to web based cessation interventions.

8.3

Monitoring/Surveillance

1. That an up to date database of available services be maintained.
2. That the database of services be publicised to facilitate access and referrals.
3. That data collected be analysed and reported on, to provide the evidence base to help
improve outcomes for the smokers wishing to quit in Ireland.
4. That regular assessment of treatment outcomes be carried out and compared to
international standards with recommendations for improvement where necessary.
5. There is need to monitor the outcomes in both quit line and web based interventions.
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Appendix 1
Census Questionnaire

RIFTFS, Irish HPH Network and IPHI
Smoking Cessation Services in Ireland
Questionnaire
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This questionnaire should be completed by the person responsible for day-today management and/or running of the smoking cessation service.
Questions will cover the following areas:


Qualifications of staff providing the program



Service structure



Participants attending the program



Location of the service



Patient record systems

All information collected in this questionnaire is for the
purpose of data compilation and will be treated in a
confidential manner and used only for its intended purpose.
Audit - Smoking Cessation Services
Smoking Cessation Service Staff Characteristics
1. Are you
a)

A smoking cessation service provider?

b)

A smoking cessation service manager?
2. If you are a SCS manager, please list the providers’ names in your region:
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3. Please select your job title from the list below:
Smoking Cessation Officer
Health Promotion Officer

Tobacco Manager

Other (please specify): ……………………

4. How long have you been in your current job? (please select one)
Less than 6 months
25 to 36 months

6 to 24 months

37 to 48 months

More than 48 months

5. Please select your professional background:
Nursing

Health Promotion

Other (please specify): …………………

6. Have you attended specific training on smoking cessation?

Yes

No

7. If yes, please indicate the type and duration of training below:
Brief Intervention training
1 day

2 days

4 days

6 days

more than 6 days

Who offered this training? ………………………………………………………………
Intensive Smoking Cessation training
1 day

2 days

4 days

6 days

more than 6 days

Who offered this training? ………………………………………………………………
Train the trainers training
1 day

2 days

4 days

6 days

more than 6 days

Who offered this training? ………………………………………………………………
8. Date of most recent training attended: …………………………………………………
9. Do you have any specific smoking cessation training needs?
10. If yes, please describe below:
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Yes

No

If you are a Smoking Cessation Service Manager, you are finished completing this
questionnaire. Please ensure that the service providers in your region complete this
questionnaire in its entirety. Thank you for your assistance.
If you are a Smoking Cessation Service Provider, please continue.

Smoking Cessation Service (SCS) Structure
11. To whom is the SCS available? (Please tick all that apply)
In-Patients

Out-Patients

Staff

Community

All of the above
12. From which of the following do you receive referrals: (Please tick all that apply)
Primary care staff (GPs, practice nurses)
Pharmacists

Dental Services

Public health nurses

Hospital midwives

Hospital consultants

Self-referral

Other (please describe): ……………………………………………………………
13. Which of the following smoking cessation services do you provide? (Please tick all that
apply)
For:

Patients

Individual advice / counselling
Group advice / counselling
Telephone advice / counselling
Info on Nicotine Replacement Therapy
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Staff

Community

Info on Zyban
Info on Champix
Other (please specify below)
14. If you deliver individual advice or counselling,
How long do individual sessions usually last?

………. Minutes

On what basis do you usually provide individual advice or counselling?
Monthly
Once only

Fortnightly

Weekly

Twice per week

Other (please specify) …………..…

15. If you deliver group advice or counseling,
How long do group sessions usually last?

………. Minutes

How many sessions normally constitute complete course of treatment? ………..
Over what period are these sessions provided?

……….Weeks

16. If you deliver telephone advice or counseling,
How long do telephone sessions usually last? ………. Minutes
On what basis do you usually provide telephone advice or counseling?
Monthly

Fortnightly

Weekly

Twice per week

Once only

Other (please specify)………….

17. Do you follow up on patients once they have received smoking cessation support?
No, none of the patients receive follow up (skip to question 19)
Yes, all patients receive follow up
Yes, but only some patients receive follow up (please describe which Patients receive
follow up in the space below)
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18. At what period do you follow up once patients have received smoking cessation
support? (Please tick all that apply)
2 weeks

1 month

3 months

6 months

1 year

Other (please specify) …………………………………………………………….
19. Do you verify self-reported successful quit attempts by CO test?
Never

Rarely

Sometimes

Often

Always

20. How many patients attended your smoking cessation service in 2006? …………..
21. Please indicate the number of patients attending your service during each of the
following periods:
Jan – Mar

Apr – Jun

Jul – Sep

Oct - Dec

..........

………

……….

1 – 50
51 – 100
101 – 150
151 – 200
201 – 250
251 – 300
> 300
Exact number

……….

(if available)
23. How many hours per week was the smoking cessation service provided in 2006?……
24. How many weeks per year was this smoking cessation service provided in 2006?……
25. Was the smoking cessation service interrupted at any time during 2006?
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Yes

No

26. If yes, why and for how long was this service interrupted?...........................................
……………………………………………………………………………………………..
27. Please tick any of the following groups that you specifically target with your smoking
cessation services:
Homeless

People who are housebound

Pregnant women

Ethnic minorities

People with disabilities

Young people

People with smoking related illnesses

Economically disadvantaged

Hospital in-patients

People with mental illness

Gay and lesbian community

Others (please specify) ………………………

28. Please use the box below to tell us specifically how your smoking cessation service is
targeting the groups selected above: (max 200 words).

29. To which geographical areas do you provide smoking cessation services? (please tick
all that apply)
Dublin

Longford

Wicklow

Offaly

Wexford

Westmeath

Carlow

Laois

Kildare

Waterford

Meath

Kerry

Louth

Tipperary

Monaghan

Galway
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Cavan

Roscommon

Kilkenny

Limerick

Cork

Sligo

Clare

Mayo

Leitrim

Donegal

31. Please indicate all the venues used to provide your SCS and how much time is spent
providing services in each venue per week.

Time spent/week

GP surgeries

__________ mins

Other primary care centre

__________ mins

Maternity hospital

__________ mins

General hospital

__________ mins

Psychiatric hospital

__________ mins

Pharmacies

__________ mins

Community centres

__________ mins

Health centres

__________ mins

Care of the elderly setting

__________ mins

Other

__________ mins

(please specify) ……………………………………………………………
Smoking Cessation Service Information Systems
32. Is the system you use to keep patient records for the smoking cessation service users:
Computer based

Paper based

Do not currently keep patient records

Other

165

(Please specify)

33. Please tick all the fields recorded in your patient record system:
Name

Address

Gender

Age

Referral source

Pregnancy

Smoking related illnesses

Other medical conditions

Smoking history (length of time smoking)
Cessation aids previously used

Number of previous quit attempts

Cessation aids currently being used

Smoking frequency

Stage of behaviour change

Print Resources provided

Medical card status

Type of intervention provided

Outcome at end of program

Follow up and status at 1 month

Follow up and status at 3 months

Follow up and status at 6 months

Others (please specify) ……………

34. If you have a separate system to collect data for analysis, is this system:
Computer based 

MS excel

Paper based

Don’t currently have a system to collect data for analysis

MS access

Other …………..………..

Other (Please specify)……………………………………………
35. Please tick all fields recorded in this system:
Patient demographics (name, address, gender, age etc)
Referral source

Pregnancy

Smoking related illnesses

Other medical conditions

Smoking history (length of time smoking)
Cessation aids previously used

Number of previous quit attempts
Cessation aids currently used
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Smoking frequency

Stage of behaviour change

Print Resources provided

Medical card status

Type of intervention provided

Outcome at end of program

Follow up and status at 1 month

Follow up and status at 3 months

Follow up and status at 6 months

Others (please specify) …………

Please use the box below to add any comments that you feel are relevant to this study: (max
200 word).

On behalf of RIFTFS, the Irish HPH Network, and the IPHI
Thank you for taking the time to complete this questionnaire.
Please return complete questionnaires by (DATE) to:
RIFTFS
The Digital Depot
Thomas Street
Dublin 8

skeogan@tri.ie
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Appendix 2
Extract from treatment database
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Appendix 3
Guidance notes on the data collection instrument/ treatment database.
This data set captures the essential information needed for the monitoring of smoking
cessation services for this TFRI/HPH/IPHI/HSE study on services in Ireland. Full, accurate
and timely completion of the data set in respect of each patient is a firm condition of
participation in this study.

Patient’s name, address, and telephone number will not be collected as part of this study.
These details should be kept as part of service records in each region/centre.

Please note that all fields in the data collection tool must be completed as a blank field
will be analysed as missing data rather than 0 or a Negative answer
e.g. Field: “Number of roll up cigarettes” should read 0 if they do not smoke them.

PATIENT CONSENT
Verbal consent should always be requested from patients for the use of data collected for
monitoring purposes. Permission should be sought for contacts made with patients at follow
up points such as 4 weeks, 3 months, etc. For the duration of this study, patients should be
informed that if they set a quit date, they will be reviewed at 4 weeks, and that CO
monitoring will form part of this review/follow-up, unless they object to having a CO test,
or if the follow-up is undertaken via a telephone call. Patients should be informed that if
they are still quit at 4 weeks, they will be offered a review at 3 months, which will also
include CO monitoring if they are still quit.
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Should a patient request that they would like no follow-up contacts, local records will need
to be clearly noted so that the patient is not contacted at 4 weeks or 3 months.

I.D. CODES/NUMBERS.


Local Patient Identifier is the very first column and can be used to store a local
patient number or a name, in order to match a patient’s details with those records kept
locally. This column does not have to be used and details from this column will not be part
of the data analysed. This column will need to be deleted before the study data are sent to
TFRI for analysis.
Service Providers and patients will be allocated ID codes for this study.



Service Provider ID codes will be unique to each individual provider, and will be
allocated on a geographical basis, thus enabling the ‘mapping’ of services.



Patient ID numbers will be numeric codes, starting with 01, and hence may differ
from ID numbers/codes that are used locally.

TREATMENT DATE
This is also referred to as Date of Assessment/Date of Registration/ Date first seen,
depending on the cessation service centre. It is the date on which a patient first meets the
service provider. If the cessation support is provided by telephone, it would be the date on
which the first support phone call takes place between patient and adviser.
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DEMOGRAPHIC DATA
Date of Birth

To be denoted as DD/MM/YYYY

Gender

Male/Female

Ethnic Groups
Western Eur

Eastern Eur

Black African

Black Caribbean

Black Other

Irish Traveller

Roman Gypsy

Oriental

Middle Eastern

Indian Subcontinent

Other

Occupation (Based on CSO Social Class Categorisation)
A detailed listing of the occupations that fall under each category are provided separately.
However, here is a quick summary of some occupations under each heading:
1 Professional workers.

E.g. doctors, pharmacists, architects, dentists, engineers (civil/

electronic/software/mining/mechanical), lecturers in third level education, judges, solicitors,
clergy, psychologists, farm owners/managers (200+ acres).

2 Managerial and Technical. E.g. Managers of banks, hotels, shops, pubs; marketing
managers; allied health professionals; nurses/ midwives; primary and secondary level teachers;
farm managers/owners (100-199 acres); senior police/prison officers.

3 Non- manual. E.g. Police officers & soldiers (sergeant and below); administrative officers
and assistants in civil service and local government; hairdressers/barbers /beauticians; educational
assistants; prof. athletes and sports officials; fire service officers; security guards; cashiers and
bank clerks, telephone operators/salespersons, auctioneers, secretaries, personal assistants,
receptionists; farm manager/owners (50-99 acres).
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4 Skilled manual. e.g.

Builders, bricklayers, painters/decorators; electricians; plumbers;

welders; motor mechanics; bakers, butchers, fishmongers, chefs, cooks; Bus/taxi drivers,
conductors and inspectors; farm manager/owner (30-49 acres).

5 Semi skilled. e.g. Tilers, roofers, glaziers; horticultural trades; waiters, bar staff; prison
service officers; assemblers and line workers; packers, bottlers; seafarers; fishing and related
workers; forestry and related workers; postal workers; porters; care assistants and attendants;
cleaners; farm manager/owner (0-29 acres).

6 Unskilled. E.g. farm workers; window cleaners; car park attendants.
7 All others gainfully employed and unknown.
PLEASE NOTE:


For those who are retired, their previous occupation should be used.



For those who are not working, e.g. a student or person working at home caring for
children or other relations, the occupation of the main income earner in the household
should be used.



For anyone who is unemployed, use their previous occupation.
Pregnant

Yes/No

TOBACCO CONSUMPTION AND DEPENDENCE
-

Daily consumption of cigarettes is to be recorded as the number of cigarettes per
day.

-

If a patient smokes roll-up cigarettes, record the number of this type of cigarette
smoked per day in the next column.

-

If a patient uses snuff or snus, please record it as ‘Y’ for ‘Yes’ in this column.
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-

Fagerstrom Score used to measure dependence level, with 3 options as answers.

FAGERSTROM SCORE – Questions

Answers

Points

Within 5 minutes

3

6 - 30 minutes

2

Yes

1

No

0

The first of the day

1

All others

0

10 or less

0

11 to 20

1

21 to 30

2

31 or more

3

Do you smoke more frequently during the first hours after waking

Yes

1

than during the rest of the day?

No

0

Do you smoke if you are so ill that you are in bed most of the day?

Yes

1

No

0

How soon after you wake do you smoke your first cigarette?

Do you find it difficult to refrain from smoking in places where it is
forbidden?

Which cigarette would you most hate to give up?

How many cigarettes per day do you smoke?

Score:
0-3 Low Addiction
4-5 Medium Addiction
6-10 High Addiction

NUMBER OF OTHERS WHO SMOKE IN THE HOUSEHOLD
Whether a smoker lives with other people who smoke no doubt influences their efforts to
quit. For this reason we have decided to record the number of other smokers in the
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household. If a smoker lives with no other smokers, insert ‘0’ in this column. If the patient
lives with one or more smokers, please insert the number of other smokers here.
PAST HISTORY RE QUITTING.
Has patient used this service before?

Has the patient used your cessation

service in the past? Please answer Yes/No.
Previous quit attempts-

This is the total number of previous quit

attempts. Please choose one of the options listed as a response.
Method used on last quit attempt-

Please record the type of support that the

patient used in their most recent quit attempt.
Options listed include:
-Cessation programme (i.e. any cessation service/support programme)
-Cessation programme (CP) plus nicotine replacement therapy (NRT)
-CP plus Zyban
-CP plus Champix
-NRT only (i.e. without behavioural support programme)
-Self motivation (i.e. cold turkey)
-Zyban only
-Champix only
-Quit line – support from National Smokers helpline
-Alternative therapies (acupuncture, hypnotherapy, laser therapy etc)
-Self-help materials (e.g. booklet they may have picked up in a pharmacy/health centre)
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CURRENT QUIT ATTEMPT
Referred by lists a number of referral sources. Referral source would not provide enough
information on the type of patient, e.g. it would not highlight that a patient was a HSE staff
member, or it would not show us which patients were in-patients.
Patient Status allows this type of patient to be recorded. The options are:


Inpatient



Outpatient



Day Patient



Public/Community – members of the public or local community. This may also
include members of a workplace who have enrolled in a support programme.



Staff members



Mental Health – patients who have mental health problems. Although we have included a
referral source of ‘Mental Health services’, it is acknowledged that a number of such
patients would actually self-refer and so their condition would not be recorded under
referral source. Hence, as they are a priority group for cessation support it was deemed
appropriate to have a category in this field by which this could be recorded.
Primary Reason for Quitting
9 reasons are listed in this field. Please record the patient’s main reason for quitting on the
current quit attempt.
GMS
There are 2 types of medical card in existence in Ireland. The original ‘Medical Card’ and
the ‘GP Only Card’. In contrast to those with a GP Only Card, people with a Medical Card
are entitled to free prescriptions. This would include prescriptions for pharmaceutical aids
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that are used to treat tobacco dependence (i.e. NRT, Zyban and Champix). Data on Medical
Card status is required in order to find out if the patient is entitled to such prescriptions. If a
patient has a GP Only Card, then the response under the GMS heading should be
‘No’.
Main Type of Support Provided
This refers to the main type of support provided on the patient’s current quit attempt. The
three main types of support are one-to-one, group and telephone but we have also
differentiated between settings such as hospital and community. Hence the options to
choose from are:
-Hospital One-to-one

-Hospital Group

-Community One-to-one

-Community Group

-Telephone

-Online

-Other
NUMBER OF CONTACTS
No. of Interventions less than 15 minutes long – this is the total no. of interventions that
took place with the patient, during the study period, that lasted 15 minutes or less. These
interventions can be face-to-face with a patient, or support delivered over the phone;
No. of Interventions longer than 15 minutes - this is the total no. of interventions that
took place with the patient, during the study period, that lasted more than 15 minutes. These
interventions can be face-to-face with a patient, or where a patient has attended group
support, or support delivered over the phone;
Administration Contacts - this includes all the following type of contacts with patients:
-Phone calls re appointments, or calls re follow-up monitoring
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-Text messages re appointments or follow-up
-Emails sent
-Letters posted
The number of occasions that attempts were made to contact a patient can be documented
as part of this figure.
PLEASE NOTE:
FOR THOSE PATIENTS WHO DO NOT SET A QUIT DATE:
- The number of interventions and number of admin. contacts with them should still
be recorded. This then completes their data set as all other columns following
Administration Contacts relate to Quit Dates and follow-up reviews.
- The Service Satisfaction Questionnaire should be given to all patients regardless of
whether they set a quit date or not. A copy of the Questionnaire, covering letter and
stamped addressed envelope should be given to each patient on their last visit, or their
last review.
- In relation to hospital patients who are seen once or twice during their hospital stay,
and who do not set a quit date or plan to return to you for an appointment, they
should be given the Satisfaction Questionnaire before they leave the hospital or it can
be posted out to them within a few days of their discharge.
- A Satisfaction Questionnaire, cover letter and envelope should be posted out to all
patients who do not receive them in person.
- Be sure to affix the ID code label provided to the questionnaire before giving it to the
patient. This ID code should match that entered into the data tool.
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QUIT DATE
Quit Date is the actual date on which the patient quits and should be denoted as
DD/MM/YYYY. Patients who set repeated “quit dates” should only be included in the
monitoring once during the period of this study, with the outcome of the latest
attempt.
In the section below on Monitoring, we have detailed the Russell Standard from the
UK, which has been adopted as guidance for monitoring. It specifies times during
which follow-up reviews should take place. To save you time, we have programmed
the data tool to automatically generate dates indicating the start and end of the 4 week
and 3 month follow up periods according to the Russell Standard once a quit date has
been entered.
The two columns next to the Quit Date are entitled ‘Start of 4 week follow-up period’ and
‘End of 4 week follow-up period’. You will see that there are already dates in these
columns (e.g. 25/01/1900 and 04/02/1900). Please ignore these but do not delete them, as
they will automatically change to a date in 2008 once you enter a quit date.
Once a quit date has been entered in the relevant column for a patient, two new dates will
appear showing you the time period during which you must carry out the 4 week review or
follow-up. For example, if a patient quits on Jan 1st, and you enter 01/01/2008 as their quit
date, the dates that will automatically appear in the next 2 columns are 26/01/2008 and
05/02/2008. This means that you can plan to review the patient anytime between Jan. 26th
and Feb. 5th.
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The data tool has also been programmed to show you their 3 month follow-up time period.
We acknowledge that it is only those patients still quit at 4 weeks that are to be followed up
at 3 months, but the data tool will give you these dates whether you need them or not.
For example, when you enter a quit date for a patient quits on 01/01/2008, you will see that
the dates that appear in the column for 3 month follow-up are 17/03/2008 and 14/04/2008,
i.e. if the patient is still quit at 4 weeks, you then review them again anytime between
March 17th and April 14th.
Method used
This aims to gather information on the use of any pharmaceutical aids on the current quit
attempt. All patients who set a quit date and receive the relevant aid(s) should be included.
Clearly the expectation is that the vast majority will use the aid as directed, but this means,
for example, that a patient who begins a course of Zyban but discontinues it (perhaps due to
side effects) should be included.
‘Cessation Programme and Combination therapy’ refers to patients who are being treated
with nicotine replacement therapy in addition to either Zyban or Champix.
FOLLOW-UP MONITORING
(A) 4 Week Follow-Up
Those patients who set a quit date must be followed up 4 weeks after the quit date, unless
the patient requested that no follow-up contact be made. If this is the case, this request can
be documented at this follow-up point (‘Patient requested No Follow-up’ is included as a
possible response on the database).
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The person who provided the initial intervention should, wherever possible, carry out the 4week follow-up.
Contacting patients for the 4 week follow-up
The Russell Standard (UK) has been adopted as guidance for reviews/follow-ups. Using
this as guidance for the 4 week review, the following applies:
For patients who have given permission to have a review or be contacted for follow-up, the
total time within which the 4 week review/follow-up must be completed is between 3 days
before and 7 days after 4 weeks post the quit date. Up to 3 attempts can be made to reach
the patient; any patient not reached after 3 attempts should be denoted as ‘Could not
Contact’. Patients should either be seen preferably in person or contacted by telephone for
follow-up.
If telephone contact is not feasible for any reason a letter should be sent. Any patient not
replying to the letter should be counted as ‘Could not Contact’.
Completing the 4 week follow-up
Definition of “Quit at 4 weeks”
According to the Russell Standard, a patient is counted as a ‘self-reported 4 week quitter’ if
they have been assessed (face to face, by postal questionnaire or by telephone) 4 weeks
after their quit date (minus 3 days or plus 7 days) and declares that he/she has not smoked a
single puff on a cigarette in the past 2 weeks.
Codes available at the 4 week follow-up include:
‘Y’ = Yes, patient still quit
‘N’ = No, patient has relapsed
‘Could not Contact’
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‘Patient RIP’
‘Patient requested No Follow-up’
Carbon Monoxide (CO) validation
CO validation should be attempted on all patients who have said they are quit at their 4
week follow-up/review (i.e. all those who have a ‘Yes’ in the previous column). CO
monitoring of patients at the 4 week follow-up stage is considered to be good practice, as it
is motivational for patients as well as a validation of their smoking status.
Codes available under ‘CO validation’ include:
‘CO (CO ≤6ppm)’ – if a patient has undergone CO validation of their quit status, and their
CO reading is 6ppm or less, they are deemed still quit and this code should be recorded
‘Self (quit status self reported)’ – if the quit status is only self report. This may happen if
the patient is not willing to return for a review, or if they refuse to undergo a CO test, or if
the follow-up takes place over the phone.
‘Fail (CO ≥7ppm)’ - if a patient has undergone CO validation of their quit status, and their
CO reading is over 7ppm, they are deemed to be not quit and this code should be recorded.
Service providers will need to ensure the regular calibration and maintenance of CO
monitors, in accordance with manufacturers’ instructions, in order to provide accurate and
consistent CO monitoring and validation.
Patients who have relapsed
It is for cessation advisers to determine whether to encourage a patient who has failed to
quit, but wishes to try again, to set a further quit date immediately. Patients who set
repeated “quit dates” should only be included in the monitoring once during the period of
this study, with the outcome of the latest attempt.
181

(B) 3 month follow-up
Only patients who have successfully quit at 4 weeks should be followed up at 3 months.
As already explained, the data tool is going to automatically show you the time period for 3
month reviews but this should only be used as guidance for those patients who were still
quit at 4 weeks.
Using the Russell Standard as guidance for the 3 month review, the following applies:
For patients who have given permission to have a review or be contacted for follow-up, the
total time within which the 3 month review/follow-up must be completed is during the
period 2 weeks either side of their follow up date, i.e. there is a 4 week period during
which patient can be contacted for follow-up;
Procedure
The same procedures for contacting a patient and undertaking CO validation should be
followed as for the 4 week follow-up.
Quit Status
A patient is counted as a ‘self-reported 3 month quitter’ if they have been assessed (face to
face, by postal questionnaire or by telephone) 3 months after their quit date (minus 14 days
or plus 14 days) and declares that he/she has not smoked more than 5 cigarettes in the
past 10 weeks.
Codes available at the 3 month follow-up include:
‘Y’ = Yes, patient still quit
‘N’ = No, patient has relapsed
‘Could not Contact’
‘Patient RIP’
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‘Patient requested No Follow-up’
Carbon Monoxide (CO) validation
CO validation should be attempted on all patients who have said they are quit at their 3
month follow-up/review (i.e. all those who have a ‘Yes’ in the previous column).
Codes available under ‘CO validation’ include:
‘CO (CO ≤6ppm)’ – if a patient has undergone CO validation of their quit status, and their
CO reading is 6ppm or less, they are deemed still quit and this code should be recorded
‘Self (quit status self reported)’ – if the quit status is only self report. This may happen if
the patient is not willing to return for a review, or if they refuse to undergo a CO test, or if
the follow-up takes place over the phone.
‘Fail (CO ≥7ppm)’ – if a patient has undergone CO validation of their quit status, and their
CO reading is over 7ppm, they are deemed to be not quit and this code should be recorded.
OPTION TO INCLUDE A COMMENTARY/SHORT REPORT
In the UK, cessation service coordinators are encouraged to complete and return ‘Quarterly
Commentaries’ with their ‘returns’ from the NHS cessation services. The Commentaries
are used to record key points arising from the monitoring (e.g. if unexpected problems have
arisen within the service, or how the service development at the end of the quarter fits with
the overall plans for the service etc.).
As part of this study, we have decided that when data tools are being returned, we will
provide an option of completing a short commentary to accompany data. Providers may
feel it important to record a comment relating to the data collection, e.g. to explain a break
in the service where no data was entered (if a provider was on leave for a period of time).
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TFRI will remind providers in advance of the end of the study that they can include a short
commentary when they submit their data tool.

Any queries should be addressed to:
Sheila Keogan
01 4893637
skeogan@tri.ie

Laura Currie
01 4893624
lcurrie@tri.ie

Paula Campbell
Work: 041 6850673 (Thursday and Friday only)
paula.campbell@maile.hse.ie (Thursday and Friday only)
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Appendix 4

Patient satisfaction questionnaire

SMOKING CESSATION SERVICE SATISFACTION QUESTIONNAIRE
WHAT WE’RE ASKING YOU TO DO –




Please try to answer every question as best as you can.
You can answer most questions by circling the relevant letter/number or by
writing in a word or phrase.
 Never circle more than one answer unless the instructions say ‘mark all
that apply’.
 Please do not consult with fellow workers, friends or relatives before
completing the questionnaire. We want your answers based on your own
experience.
 Please do NOT write your name anywhere on the questionnaire. Your
answers are strictly confidential and your service provider will not see them.
THANK YOU VERY MUCH FOR YOUR COOPERATION.

1.

If you were to attend a service to help you quit smoking, what day of the week
would you prefer to attend?

A.

Weekends

B.

Weekdays

2.

At what time of day would you prefer to attend a smoking cessation support
service?

A.

Mornings

B.

Afternoons

C.

Evenings
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3.

How long did you have to wait for your first smoking cessation support appointment
after contacting the service or being referred?

A.

Less than 1 week

B.

1 to 2 weeks

C.

2 – 4 weeks

D.

More than 4 weeks

E.

Don’t know

4.

What form of support do you feel would be most helpful in supporting your quit
attempt? Mark all that apply.

A.

Group Support

B.

Individual Support (one on one)

C.

Telephone Support

D.

Online Support

E.

Other (Please specify)
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Please rate the extent to which you agree with each of the following statements. Circle the appropriate number on the scale from 1 to
5
Q No

Statements

Strongly

Disagree

Disagree

Don’t

Agree

know

Strongly
Agree

The location of the service was convenient for me.

1

2

3

4

5

The time of day that the service was provided suited me.

1

2

3

4

5

The day of week the service was provided suited me.

1

2

3

4

5

The venue in which the service was provided was

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

suitable.
The smoking cessation support provided met my
expectations.
.

I would feel confident recommending this service to
friends and family.

.

The staff that provided the support service seemed well
trained to do so.

.

The staff providing the service explained information
clearly.

.

The staff providing the service listened to and
understood my concerns.

.

Overall I am very satisfied with the support I have
received at this service.
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Q No

Statements

Strongly

Disagree

Disagree
.

15 The time I had to wait between first contacting the service

Don’t

Agree

know

Strongly
Agree

1

2

3

4

5

1

2

3

4

5

and receiving my first appointment was reasonable.
.

16

I was given all the information I required to support my quit
attempt.

.

17

I felt free to ask my service provider questions at any time.

1

2

3

4

5

.

18

The information I received was helpful in my attempt to quit

1

2

3

4

5

1

2

3

4

5

smoking.
.

19

The support given to me made me feel more motivated and
confident to make my quit attempt.

.

20

The length of support session(s) was long enough.

1

2

3

4

5

.

21

The number of support sessions was suitable.

1

2

3

4

5

.

22

The staff providing the service was supportive and caring.

1

2

3

4

5
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23.

Would you access this service again in the future if you needed further support to quit
smoking?

A.

Yes

B.

No

If you answered no, please explain why you would not access this service again.

24.

25.

Please provide one way that this cessation service can improve support for smokers.

If you were prescribed nicotine replacement therapy (eg patches, gum etc.) or medications
(eg Zyban or Champix) to help you stop smoking, did you have to pay for them?

A.

Yes

B.

No

C.

I was not prescribed medications.
If Yes, did this limit your participation in the cessation programme?

A.

Yes
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B.

No

26. What is your gender?
A.

Male

B.

Female

27. What is your date of birth:

Date_____Month_______Year_______

Thank you very much for taking the time to complete this questionnaire your comments will help us
to improve services in Ireland. Please use the stamped addressed envelope to return the
questionnaire.
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